US.ABBV · AbbVie

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.896132059537878,
        "turnoverUsdM": 932.5603492787401,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.ABBV",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 239.9,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.8,
      "take_profit_price": 270.0637,
      "target_multiplier": 1.9,
      "technical_strength": 1.65,
      "take_profit_percent": 6.1
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.792264119075756,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 69.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 236.568,
    "ma50": 220.7796,
    "close": 254.65,
    "prevClose": 254.76,
    "avgVolume20": 8953006,
    "volumeRatio": 0.41,
    "changePercent": -0.04
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": 0.001336911643269989,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 0.40321370747312507,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.9177685023706343,
      "volat_points": 0,
      "day_range_pct": 0.0238759483163537,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 69.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 66,
        "contribution": 3.3
      },
      {
        "raw": 17.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 86,
        "contribution": 17.2
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 21.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 72,
        "contribution": 21.6
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 61.5,
    "details": [
      "基本面分析總分: 3.3/5分",
      "資金流分析總分: 17.2/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 21.6/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.3,
      "資金流": 17.2,
      "市場環境": 8.6,
      "情緒分析": 2,
      "技術信號": 21.6,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 932.5603492787401,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 4,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.ABBV",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.57
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 720.4330052000001,
                "ma50": 711.66400144,
                "name": "QQQ",
                "close": 709.42999,
                "points": 0.4
              },
              "spy": {
                "ma20": 741.2935059,
                "ma50": 739.0122021000002,
                "name": "SPY",
                "close": 747.71002,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.896132059537878,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 1,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140833000,
                "url": "https://finnhub.io/api/news?id=d87c00bc4ffcd2c79d987e70e9109afe7c2658d46040ac650e3928d4dc945e6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.",
                "category": "company",
                "datetime": 1783437120,
                "headline": "EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma"
              },
              {
                "id": 140803756,
                "url": "https://finnhub.io/api/news?id=a58a14997540260a608f155893638578192d86ea1eeff804e732eca8a828374f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "U.S. lawmakers have opened a bipartisan national security investigation into AbbVie (NYSE:ABBV) and other pharmaceutical companies. The inquiry focuses on AbbVie’s clinical trials in China, including work at facilities reportedly linked to the Chinese military and sites in the Xinjiang region. Congress has requested detailed information on research practices, data protection, and site vetting, with responses due by mid-July. AbbVie is a large U.S. pharmaceutical company with a portfolio...",
                "category": "company",
                "datetime": 1783120245,
                "headline": "AbbVie (ABBV) Faces Congressional Probe Over China Clinical Trials"
              },
              {
                "id": 140803319,
                "url": "https://finnhub.io/api/news?id=2c90bdd8ac7913cd59660500bf0f8ea97554b2add782260b8e8aabb463800f68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
                "category": "company",
                "datetime": 1783111326,
                "headline": "Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks"
              },
              {
                "id": 140784681,
                "url": "https://finnhub.io/api/news?id=d35969a03c88f7ed247ee336329b0cc2cda95264dc6ecae1213e3facdbc71d4d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now. On June 19, AbbVie Inc. (NYSE:ABBV) delivered topline Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress. The results from the Phase 3 CLL14 trial affirm venetoclax’s enduring safety and efficacy in untreated chronic […]",
                "category": "company",
                "datetime": 1782935618,
                "headline": "AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment"
              },
              {
                "id": 140772835,
                "url": "https://finnhub.io/api/news?id=665f2c490c7dd2d76a1065546e4054c5eedb00e8b49ac907627ee868a18867d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1782824409,
                "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140766757,
                "url": "https://finnhub.io/api/news?id=918de8eec43ac12578e825b6e733c16be796588f5d3443db14b645476cfc0110",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June 27, AbbVie Inc. (NYSE:ABBV) said the Food and Drug Administration approved Skyrizi for pediatric patients with psoriasis. The company said Skyrizi, or risankizumab-rzaa, can now be used in patients aged six years and […]",
                "category": "company",
                "datetime": 1782764507,
                "headline": "Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy?"
              },
              {
                "id": 140764019,
                "url": "https://finnhub.io/api/news?id=d597af50be4a2272154a41f812c33ed0cd7fb95794ce8540da4fc8779fe53b8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If you are trying to figure out whether AbbVie stock still offers value after its recent performance, starting with a clear view of price versus fundamentals is essential. AbbVie has recently traded at US$253.35, with returns of 10.1% over 7 days, 16.4% over 30 days, 10.5% year to date, 40.9% over 1 year, 109.0% over 3 years and 165.3% over 5 years, which has naturally focused attention on whether the current price fairly reflects the business. Recent headlines have focused on AbbVie’s...",
                "category": "company",
                "datetime": 1782753277,
                "headline": "AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check"
              },
              {
                "id": 140764020,
                "url": "https://finnhub.io/api/news?id=75fb30d42939fd5cd6076f6e46d8c56fbe7d7fc746c8195cfd3c1aa385de069e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata and non-segmental vitiligo. If approved, RINVOQ could become the first systemic therapy for non-segmental vitiligo in Europe. The new indications target areas with high unmet medical need in dermatology and immunology. AbbVie has been active across immunology, gastroenterology and virology, and RINVOQ is already a core asset in its portfolio. These fresh CHMP...",
                "category": "company",
                "datetime": 1782749312,
                "headline": "AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe"
              }
            ],
            "raw_source": [
              {
                "id": 140832980,
                "url": "https://finnhub.io/api/news?id=2dc284d74d2dfa92cafc7a18267544557390f574879e078572b9bd9fedd52509",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.",
                "category": "company",
                "datetime": 1783437300,
                "headline": "PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?"
              },
              {
                "id": 140833000,
                "url": "https://finnhub.io/api/news?id=d87c00bc4ffcd2c79d987e70e9109afe7c2658d46040ac650e3928d4dc945e6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.",
                "category": "company",
                "datetime": 1783437120,
                "headline": "EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma"
              },
              {
                "id": 140831345,
                "url": "https://finnhub.io/api/news?id=52f63859eb14de7cfd9591ec5270eff9343bcf991eeb565cc6a985d87a3bb440",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "It doesn't get much more dependable and lucrative than the healthcare industry.",
                "category": "company",
                "datetime": 1783436700,
                "headline": "3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)"
              },
              {
                "id": 140829985,
                "url": "https://finnhub.io/api/news?id=a2c319bbbc8e3b1a563879d34b591d087f4e2206a20aa53e78918dae2961aa6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Updates with stock and oil price moves, and additional details from sixth paragraph onward.) US",
                "category": "company",
                "datetime": 1783428864,
                "headline": "Update: Tech Stock Decline, Oil Price Increase Dampen US Equity Futures Pre-Bell"
              },
              {
                "id": 140829362,
                "url": "https://finnhub.io/api/news?id=bb3c7a7fd97eed7d872569c0b0c95817ef6f14185352ec2228f8fa15528dd83d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
                "category": "company",
                "datetime": 1783425712,
                "headline": "3 Market-Beating Stocks Worth Investigating"
              },
              {
                "id": 140830081,
                "url": "https://finnhub.io/api/news?id=580936ad414b3921c64f1dc21555311d813c506bf71f924d23f4f284fe28de1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine firing on all cylinders, and a home improvement giant priced for a ... 3 Dividend Aristocrats to Buy in July",
                "category": "company",
                "datetime": 1783425623,
                "headline": "3 Dividend Aristocrats to Buy in July"
              },
              {
                "id": 140832414,
                "url": "https://finnhub.io/api/news?id=7da8f1eb7ec5d5cbc7857bf0adf3675e865eeb20787b7e266f148af2de3f8a63",
                "image": "https://image.cnbcfm.com/api/v1/image/108297751-1777306856555-108297751-1777306739591-gettyimages-2241685449-299621final.jpeg?v=1777306869&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "This summer, Jefferies recommends focusing on some high-quality stocks that have been left behind by the AI momentum trade.",
                "category": "company",
                "datetime": 1783424733,
                "headline": "Buy these quality, low-stress stocks for the summer, says Jefferies"
              },
              {
                "id": 140828385,
                "url": "https://finnhub.io/api/news?id=3e2d22bf0fe9e5bc3117b2a7df38db19909b54e7a4c7266d015a4543841be531",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Look for history to repeat itself with Apple's latest pullback.",
                "category": "company",
                "datetime": 1783415040,
                "headline": "Is Apple Stock a Buy After Its Recent Pullback? Here's What History Suggests."
              },
              {
                "id": 140830044,
                "url": "https://finnhub.io/api/news?id=a525b2f107ac14ff07317a5d0fd2a984f07cf0426b0135b325b8d65da9b43696",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.",
                "category": "company",
                "datetime": 1783413771,
                "headline": "Can anyone catch up to Eli Lilly?"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140823588,
                "url": "https://finnhub.io/api/news?id=ddff0ace2d7ef2d65edf1d86bc46735f872c44ab2e339ed948872a65db162ebb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Dividend funds pulled in $24.1 billion in the first quarter of 2026, their strongest opening quarter in four years, and a lot of that cash went looking for a boring place to hide from AI-hype exhaustion. The iShares Core High Dividend ETF (NYSEARCA:HDV) is one of them. HDV holds 75 positions, charges 0.08%, and yields ... A 2.86% Yield, 0.08% Fee, and 75 Stocks: Is HDV the Anti-Hype ETF?",
                "category": "company",
                "datetime": 1783364742,
                "headline": "A 2.86% Yield, 0.08% Fee, and 75 Stocks: Is HDV the Anti-Hype ETF?"
              },
              {
                "id": 140822487,
                "url": "https://finnhub.io/api/news?id=eea89ce3e9d025387b685726f6e8051076784666f8347fa13d3a0f89813cb105",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 trial, which evaluated fixed-duration TEPKINLY in combination with R2 compared to standard of care R2.",
                "category": "company",
                "datetime": 1783359900,
                "headline": "AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma"
              },
              {
                "id": 140824914,
                "url": "https://finnhub.io/api/news?id=c34220ce72092184875ca3f709d83515b4d797e53899ba0a95a3f1e52fe9b073",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable",
                "category": "company",
                "datetime": 1783354483,
                "headline": "AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61"
              },
              {
                "id": 140821033,
                "url": "https://finnhub.io/api/news?id=4c61cc364714533bd4f04c0f59c93534543bbcf3cc26ac7b0713b270e8efaada",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.",
                "category": "company",
                "datetime": 1783352496,
                "headline": "Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into Earnings"
              },
              {
                "id": 140821034,
                "url": "https://finnhub.io/api/news?id=65c5fe79f348769158d94604c63c830cdd5ebdaaaf0ad0c38b1a70992d53e932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over",
                "category": "company",
                "datetime": 1783350767,
                "headline": "Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says"
              },
              {
                "id": 140822443,
                "url": "https://finnhub.io/api/news?id=e98b4572e6d9ffe70502143f9879e30e50ff8303c76022fdc0e9700f2d9eb925",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.",
                "category": "company",
                "datetime": 1783349400,
                "headline": "Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?"
              },
              {
                "id": 140824915,
                "url": "https://finnhub.io/api/news?id=dd7277f1774d52e22cb90c2b9ce7af171148e6eca2ba2d877f4e4717df18a20a",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the second-line setting,",
                "category": "company",
                "datetime": 1783345877,
                "headline": "AbbVie’s TEPKINLY + R2 Becomes First Bispecific Therapy Approved In Europe For Relapsed Follicular Lymphoma Following Phase 3 Success"
              },
              {
                "id": 140818670,
                "url": "https://finnhub.io/api/news?id=5bb378871c4d7250110c755b530ad54ad40bcf2da5fe3ace6f349cc9076ef393",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_48_b0208efde3.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Thursday's jobs report came in far below forecasts, initially easing pressure on the Federal Reserve, before a fresh slide in memory and semiconductor stocks dragged the Nasdaq lower even as the Dow closed at a record. Tesla sold off despite its best delivery quarter in years, healthcare names caught a bid, and SK Hynix lined up what would be the largest US listing ever by a foreign company.",
                "category": "company",
                "datetime": 1783331949,
                "headline": "Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway."
              },
              {
                "id": 140819912,
                "url": "https://finnhub.io/api/news?id=b5d2bd20e0a76d685d7676d5181354c92bbb779edc1b0cc1076343be0a7f6da6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/628093148/image_628093148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they lag AI names. Click for the picks.",
                "category": "company",
                "datetime": 1783331728,
                "headline": "My Top 5 Pharma Stocks Wall Street Ignores"
              },
              {
                "id": 140819213,
                "url": "https://finnhub.io/api/news?id=df54ac1f1d0803a2ae3f936412cc7e5caa55e3e9d7b448d238ec0a4bee9c721c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AMAT, MA, ABBV, VATE and BOF headline new research reports highlighting AI, payments, healthcare and microcap growth opportunities.",
                "category": "company",
                "datetime": 1783329720,
                "headline": "The Zacks Analyst Blog Highlights Applied Materials, Mastercard, AbbVie, INNOVATE and BranchOut"
              },
              {
                "id": 140824916,
                "url": "https://finnhub.io/api/news?id=13df82dd6410a056426443863efab21b385c133c37e683b13ee800cdbe5514e2",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $240 to $265.",
                "category": "company",
                "datetime": 1783327768,
                "headline": "Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $265"
              },
              {
                "id": 140814545,
                "url": "https://finnhub.io/api/news?id=7762ea644fb03778da654b93f7dfa933d7c1234ba00dfef0d0d4b7426470cfe5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend 100 Index, which requires 10 consecutive years of dividend payments and screens on cash flow to ... Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year",
                "category": "company",
                "datetime": 1783273647,
                "headline": "Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year"
              },
              {
                "id": 140803756,
                "url": "https://finnhub.io/api/news?id=a58a14997540260a608f155893638578192d86ea1eeff804e732eca8a828374f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "U.S. lawmakers have opened a bipartisan national security investigation into AbbVie (NYSE:ABBV) and other pharmaceutical companies. The inquiry focuses on AbbVie’s clinical trials in China, including work at facilities reportedly linked to the Chinese military and sites in the Xinjiang region. Congress has requested detailed information on research practices, data protection, and site vetting, with responses due by mid-July. AbbVie is a large U.S. pharmaceutical company with a portfolio...",
                "category": "company",
                "datetime": 1783120245,
                "headline": "AbbVie (ABBV) Faces Congressional Probe Over China Clinical Trials"
              },
              {
                "id": 140803319,
                "url": "https://finnhub.io/api/news?id=2c90bdd8ac7913cd59660500bf0f8ea97554b2add782260b8e8aabb463800f68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
                "category": "company",
                "datetime": 1783111326,
                "headline": "Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks"
              },
              {
                "id": 140803320,
                "url": "https://finnhub.io/api/news?id=695e2d3b685b222b18f04565931b512bb3994d5ed7ed3dbad5299a66ee405633",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The average Social Security retirement check reached $2,081 per month as of April 2026, according to the Social Security Administration’s monthly statistical data. That figure carries the 2.8% cost-of-living adjustment that took effect in January 2026. Replacing roughly that amount with dividend income is a math problem before it is an investing problem, and the ... Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.",
                "category": "company",
                "datetime": 1783110124,
                "headline": "Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It."
              },
              {
                "id": 140802850,
                "url": "https://finnhub.io/api/news?id=c5905c968be2d149392bf23b184b1bb711768e2b822b0fb6621edca56d2e06a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.",
                "category": "company",
                "datetime": 1783100460,
                "headline": "WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?"
              },
              {
                "id": 140799160,
                "url": "https://finnhub.io/api/news?id=924f5c6ddc89f1c2bb6d7af8eb7f121f90676c1e22c42140a348f3b05f08a402",
                "image": "https://www.chartmill.com/images/uploads/cannabis_theme_f843462963.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Recent cannabis theme strength is driven by large, profitable firms like AbbVie, Altria, and Jazz Pharma, not pure-play operators. These cash-flow giants offer value, momentum, and defensive income.",
                "category": "company",
                "datetime": 1783082137,
                "headline": "Cannabis Theme Rally Powered by Profitability, Not Pure-Play Speculation"
              },
              {
                "id": 140798743,
                "url": "https://finnhub.io/api/news?id=840d41f2aa0e747f2602ed1773f4dbb206a469c2fa2c4c15ce0627a85dc8e190",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/457980515/image_457980515.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Plan a flexible retirement strategy with dividend growth stocks, Fidelity savings milestones, and a smart shift to REITs/MLPs for income. Click here to read in detail.",
                "category": "company",
                "datetime": 1783063800,
                "headline": "The Best Retirement Ever? Here's How I'm Preparing For It"
              },
              {
                "id": 140795000,
                "url": "https://finnhub.io/api/news?id=9bdd4ead6ca463f39ccd79eec507d4ea14a994f40aa974f3f6a68e54863469d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Applied Materials is riding AI-driven chip demand, but can record margins, new products and China-related risks shape its next phase of growth?",
                "category": "company",
                "datetime": 1783025220,
                "headline": "Top Research Reports for Applied Materials, Mastercard & AbbVie"
              },
              {
                "id": 140794037,
                "url": "https://finnhub.io/api/news?id=d34b320aa80113fce02e54c7d0e2a3e9dd50198bf09c66427dc6a9583845cac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State",
                "category": "company",
                "datetime": 1783020874,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 140792979,
                "url": "https://finnhub.io/api/news?id=e3abb4735d28fe1ce35ae74f2a97593a9c387c3bc2375ef13f3b1e09dbb5d3b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S",
                "category": "company",
                "datetime": 1783014167,
                "headline": "Sector Update: Healthcare Stocks Gain Thursday Afternoon"
              },
              {
                "id": 140792959,
                "url": "https://finnhub.io/api/news?id=ee6da6462659dfa08361afe62be1aecd7ac76b797f01f38b6a14f5d8d0d35fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.",
                "category": "company",
                "datetime": 1783013373,
                "headline": "JNJ Stock Management Sees A Breakout, The Market Sees A Standoff"
              },
              {
                "id": 140792961,
                "url": "https://finnhub.io/api/news?id=56ace9e8f9a3601c5c52f7e264cce2da28a30e17b535a2b0bb8be19b8729298e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...",
                "category": "company",
                "datetime": 1783008180,
                "headline": "House committee investigates Merck, AbbVie over China trials"
              },
              {
                "id": 140800595,
                "url": "https://finnhub.io/api/news?id=d496e3fa576899848e38d53aa49bd5f7bcaf860c9b143f35ea2324fecbf3ac1c",
                "image": "https://image.cnbcfm.com/api/v1/image/108330186-1783019122904-1783018967-46914473154-hd.jpg?v=1783019124&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "Jeff Kilburg, founder and CEO of KKM Financial, joins \"Power Lunch\" to discuss the growing interest in healthcare stocks.",
                "category": "company",
                "datetime": 1783004742,
                "headline": "KKM's Jeff Kilburg explains the healthcare trade in the second half of 2026"
              },
              {
                "id": 140791369,
                "url": "https://finnhub.io/api/news?id=8f621558b61102a48e8c285c181fa3664698730dc9ad55bb696a893b9fcd3e20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.",
                "category": "company",
                "datetime": 1782996960,
                "headline": "J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?"
              },
              {
                "id": 140790469,
                "url": "https://finnhub.io/api/news?id=816846b83f430a7c3a1a8ae584f783339e682b493c947e7c9179c87113b4f899",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Dividend investors entering July 2026 have a rare setup: Three of the market’s most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year. The thesis is simple. When defensive cash-flow machines start outperforming, ... 3 Dividend Stocks to Buy Hand Over Fist in July",
                "category": "company",
                "datetime": 1782993608,
                "headline": "3 Dividend Stocks to Buy Hand Over Fist in July"
              },
              {
                "id": 140790463,
                "url": "https://finnhub.io/api/news?id=10f0b33a809a877b563a9f52ce1db4964c98a359ae660cae66a446c49b226eb3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.",
                "category": "company",
                "datetime": 1782984578,
                "headline": "Can pharma sustain its $2T trajectory?"
              },
              {
                "id": 140787371,
                "url": "https://finnhub.io/api/news?id=a662d639b6bd16faa2bfb536dd730a5e609e369c2bf7dfc7241cfbcaf28e4ec3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See more on ABBV here.",
                "category": "company",
                "datetime": 1782953254,
                "headline": "AbbVie: Apogee Deal Just Widened An Already Dominant Moat"
              },
              {
                "id": 140784680,
                "url": "https://finnhub.io/api/news?id=71d9259a1320c76a04f6b4c8ddaa267b09c0ca5af6e3ff186b2adf38651350e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock. This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that […]",
                "category": "company",
                "datetime": 1782941013,
                "headline": "H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News"
              },
              {
                "id": 140784681,
                "url": "https://finnhub.io/api/news?id=d35969a03c88f7ed247ee336329b0cc2cda95264dc6ecae1213e3facdbc71d4d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now. On June 19, AbbVie Inc. (NYSE:ABBV) delivered topline Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress. The results from the Phase 3 CLL14 trial affirm venetoclax’s enduring safety and efficacy in untreated chronic […]",
                "category": "company",
                "datetime": 1782935618,
                "headline": "AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment"
              },
              {
                "id": 140780678,
                "url": "https://finnhub.io/api/news?id=e2749f58987f30e37f1829e51d353bb5b68f73ac9e497b0da9b369012ed605a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.",
                "category": "company",
                "datetime": 1782912420,
                "headline": "J&J's Innovative Medicine Business in Q2: Here's What to Watch"
              },
              {
                "id": 140778730,
                "url": "https://finnhub.io/api/news?id=e2fcf33f60826a49fdade2c0b1ffdc94ad50ba1be20534ca38bb0df86bb3f811",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The iShares MSCI USA Momentum Factor ETF (NYSEARCA:MTUM) has run hard this year, climbing 30% year to date and 38% over the past 12 months to roughly $326. Headline numbers, though, mask a violent rotation inside MTUM’s portfolio. The AI/cloud mega-caps that powered the momentum trade through 2025 have stumbled, while one AI-memory name has ... MTUM Investors: Watch Micron’s Weight at the November Reconstitution",
                "category": "company",
                "datetime": 1782906956,
                "headline": "MTUM Investors: Watch Micron’s Weight at the November Reconstitution"
              },
              {
                "id": 140785458,
                "url": "https://finnhub.io/api/news?id=342506985faebf34d7bded00442e0acd28a3ddea10ca61840ee82c35bd9081e6",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.03% on an annualized basis producing an average annual return of 16.59%. Currently, AbbVie has a market capitalization of $442.79 billion.",
                "category": "company",
                "datetime": 1782905444,
                "headline": "Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today"
              },
              {
                "id": 140778787,
                "url": "https://finnhub.io/api/news?id=4059fc2e083439040224e3484f51bebf3b6108688736c2ad1aae17b7fcfac049",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours. Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announc",
                "category": "company",
                "datetime": 1782903600,
                "headline": "Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director"
              },
              {
                "id": 140775242,
                "url": "https://finnhub.io/api/news?id=02b91b29d4d6866e764fad5d9b5d883e4c856174563540aa0f7ce0aaf8483c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.",
                "category": "company",
                "datetime": 1782851051,
                "headline": "Why Is JNJ Stock Defying The Market’s Daily Mood Swings?"
              },
              {
                "id": 140775187,
                "url": "https://finnhub.io/api/news?id=709b02be3fd32eb008f5b42a7a660985758c33209662d74b31216c8345d1c36f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie knows how to plan ahead.",
                "category": "company",
                "datetime": 1782849900,
                "headline": "This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?"
              },
              {
                "id": 140774512,
                "url": "https://finnhub.io/api/news?id=60d4e872b38b8a51020c9e003ba137fc0486811d85f7026d6e974ba19d46aa88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%",
                "category": "company",
                "datetime": 1782848500,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 140773506,
                "url": "https://finnhub.io/api/news?id=3ab4dfd96abdfe37327fb0d9480fd0a8290b9f1d3cbfe26e38b29b5d96d5f202",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.",
                "category": "company",
                "datetime": 1782837240,
                "headline": "What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?"
              },
              {
                "id": 140773471,
                "url": "https://finnhub.io/api/news?id=b60fbb2c0ce1fb45c8387013f66392ad1bc0f85028dedac5e289199b0afaea57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...",
                "category": "company",
                "datetime": 1782836340,
                "headline": "Merck, AbbVie probed by US lawmakers over China clinical trials: report"
              },
              {
                "id": 140781677,
                "url": "https://finnhub.io/api/news?id=ab65f7a3201d95ef11cd96835570ff682d86a3d9510e670ecc990714c0d3509f",
                "image": "https://image.cnbcfm.com/api/v1/image/108264191-1770764453454-gettyimages-2259521349-img_7851.jpeg?v=1770764487&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1782825385,
                "headline": "Stocks making the biggest moves midday: AeroVironment, Abivax, Astera Labs, Watts Water Technologies & more"
              },
              {
                "id": 140772835,
                "url": "https://finnhub.io/api/news?id=665f2c490c7dd2d76a1065546e4054c5eedb00e8b49ac907627ee868a18867d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1782824409,
                "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140771981,
                "url": "https://finnhub.io/api/news?id=1b0f26a15d0484950f3723cd1a9eeaeda916aa55b962ae7710464a962924f4e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in Xinjiang",
                "category": "company",
                "datetime": 1782824140,
                "headline": "Merck, AbbVie investigated over China military hospital drug trials"
              },
              {
                "id": 140773978,
                "url": "https://finnhub.io/api/news?id=a995511872549cded0d975ae29ed1463c2fffffbd1e1ce97f4d050b394c62d0e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/lab--Medical-Hospital-Research-Laborator.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.",
                "category": "company",
                "datetime": 1782822706,
                "headline": "Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity"
              },
              {
                "id": 140773371,
                "url": "https://finnhub.io/api/news?id=f2c075bb05deff66a588a13b14e2590c15ab7656bffa4c90b601b4002f8b94a7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221626716/image_2221626716.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Market leadership has narrowed as the Magnificent Seven have shed $5 trillion in market cap from its peak. Read more about the warning signs for investors.",
                "category": "company",
                "datetime": 1782820533,
                "headline": "U.S. Equity Markets: Lots Of Gambling Going On"
              },
              {
                "id": 140771584,
                "url": "https://finnhub.io/api/news?id=6c754633791e8e46d89dc976069416ae410eb3a21e59837ad76cd1b1e0936bb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US Hous",
                "category": "company",
                "datetime": 1782819184,
                "headline": "Market Chatter: AbbVie, Merck Investigated by US House Committee Over Clinical Trials in China"
              },
              {
                "id": 140781710,
                "url": "https://finnhub.io/api/news?id=3df3441b99c591d54c3f5c8a360b236c02f57bee97df464f2bc66c2ef6f772a3",
                "image": "https://image.cnbcfm.com/api/v1/image/108328691-3ED1-REQ-063026-NewsOPEN.jpg?v=1782827583&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1782813641,
                "headline": "Market Open: June 30, 2026"
              },
              {
                "id": 140772368,
                "url": "https://finnhub.io/api/news?id=3baa0b6d8130b52153c4c742a502edc285b76c9502f66aef88dfb9d8fc3d6dd9",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1782813049,
                "headline": "U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials"
              },
              {
                "id": 140772369,
                "url": "https://finnhub.io/api/news?id=e00ce0091248ea12ffc6edc03cf742025d4e18a34a9a0f800f183d3a3e993f4c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials conducted in China.",
                "category": "company",
                "datetime": 1782810790,
                "headline": "Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report"
              },
              {
                "id": 140771174,
                "url": "https://finnhub.io/api/news?id=a779f37349a932b7eac725daaa9c57d53cf2e373883489d6077c5804e08973c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaborationUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales Tokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reache",
                "category": "company",
                "datetime": 1782808020,
                "headline": "Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases"
              },
              {
                "id": 140781711,
                "url": "https://finnhub.io/api/news?id=02d91ccebaaebf5085bf9b485c8b12d7b5bd1bd29f0076b7a6472ba09dd6d4c7",
                "image": "https://image.cnbcfm.com/api/v1/image/107384812-1709909242625-gettyimages-1124366588-20190212-dm-gtyworldagexpo-05.jpeg?v=1751374629&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1782804461,
                "headline": "Stocks making the biggest moves premarket: AeroVironment, Strategy, Merck & more"
              },
              {
                "id": 139930306,
                "url": "https://finnhub.io/api/news?id=7c7bc27315adbe5bcfe5ed5e35cd4e6dcc9d016797069c983e56b5235fa1d71d",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1782799815,
                "headline": "How Your Taxes Will Be Different Next Year, And Why You'll Have Trump To Thank"
              },
              {
                "id": 140766757,
                "url": "https://finnhub.io/api/news?id=918de8eec43ac12578e825b6e733c16be796588f5d3443db14b645476cfc0110",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June 27, AbbVie Inc. (NYSE:ABBV) said the Food and Drug Administration approved Skyrizi for pediatric patients with psoriasis. The company said Skyrizi, or risankizumab-rzaa, can now be used in patients aged six years and […]",
                "category": "company",
                "datetime": 1782764507,
                "headline": "Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy?"
              },
              {
                "id": 140766758,
                "url": "https://finnhub.io/api/news?id=edf41837609d78e261fc479ad9112ca1cc3591abfeac8f74be0859a6e9f3a271",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of therapy. Based on topline results from the prespecified primary analysis, the trial met its primary endpoint, demo",
                "category": "company",
                "datetime": 1782764100,
                "headline": "AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma"
              },
              {
                "id": 140765416,
                "url": "https://finnhub.io/api/news?id=95a85c6616a1501f68624ef59ae95118582b4bae62be2a70cc74e23ab2cfc456",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.",
                "category": "company",
                "datetime": 1782758026,
                "headline": "AbbVie Stock Rockets 17% With 5-Day Winning Streak"
              },
              {
                "id": 140765417,
                "url": "https://finnhub.io/api/news?id=54fca79a72ef6ab10f321f3b9a76224d1539a3dba8e92484bc7fdf1e835ee63d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.",
                "category": "company",
                "datetime": 1782754652,
                "headline": "Should You Chase The Breakout In Eli Lilly Stock?"
              },
              {
                "id": 140766531,
                "url": "https://finnhub.io/api/news?id=e9a2d8df8fe3d265cae855305ce25afe0c53a9bb633ad80629a2843f33f5b8a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220268222/image_2220268222.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Sector outlook for 2H 2026: XLK downgraded, XLI/XLU upgraded, XLY/XLC underperform. Click here to read the analysis in detail.",
                "category": "company",
                "datetime": 1782754200,
                "headline": "My S&P 500 Prediction On Sector Outperformers And Underperformers For 2H/2026"
              },
              {
                "id": 140764019,
                "url": "https://finnhub.io/api/news?id=d597af50be4a2272154a41f812c33ed0cd7fb95794ce8540da4fc8779fe53b8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If you are trying to figure out whether AbbVie stock still offers value after its recent performance, starting with a clear view of price versus fundamentals is essential. AbbVie has recently traded at US$253.35, with returns of 10.1% over 7 days, 16.4% over 30 days, 10.5% year to date, 40.9% over 1 year, 109.0% over 3 years and 165.3% over 5 years, which has naturally focused attention on whether the current price fairly reflects the business. Recent headlines have focused on AbbVie’s...",
                "category": "company",
                "datetime": 1782753277,
                "headline": "AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check"
              },
              {
                "id": 140766217,
                "url": "https://finnhub.io/api/news?id=488e3e2c93c13800334fb14b1876f80a9a8aa7c1ac7f6c72ca089bd9f5f3ff34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241146296/image_2241146296.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and growth. Click here to read more.",
                "category": "company",
                "datetime": 1782752400,
                "headline": "Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It"
              },
              {
                "id": 140768190,
                "url": "https://finnhub.io/api/news?id=60f5db0ec6f8c523c2433421bb7ba2ca6973e1dd02d5b3268f4367bdcdbc96b4",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS)",
                "category": "company",
                "datetime": 1782749914,
                "headline": "AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival"
              },
              {
                "id": 140764020,
                "url": "https://finnhub.io/api/news?id=75fb30d42939fd5cd6076f6e46d8c56fbe7d7fc746c8195cfd3c1aa385de069e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata and non-segmental vitiligo. If approved, RINVOQ could become the first systemic therapy for non-segmental vitiligo in Europe. The new indications target areas with high unmet medical need in dermatology and immunology. AbbVie has been active across immunology, gastroenterology and virology, and RINVOQ is already a core asset in its portfolio. These fresh CHMP...",
                "category": "company",
                "datetime": 1782749312,
                "headline": "AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe"
              },
              {
                "id": 140764004,
                "url": "https://finnhub.io/api/news?id=157b2da2f44df7243da25e74d43797d4e8b9ef60702fa15a9eb2006a9b5c901c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.",
                "category": "company",
                "datetime": 1782748982,
                "headline": "3 No-Brainer Dividend Stocks to Buy Right Now"
              },
              {
                "id": 140762416,
                "url": "https://finnhub.io/api/news?id=b4bfa78b420856d3cf1dfa1544fc0b60ab0d4ff3eea73e0b465cfbaa29973a51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In the past five years, this top healthcare stock has risen by close to 130%.",
                "category": "company",
                "datetime": 1782747690,
                "headline": "AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?"
              },
              {
                "id": 140764022,
                "url": "https://finnhub.io/api/news?id=77813857b9ba382b77864c3ccb8f89e428a0ed0a9e991af93898e5174f917812",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.",
                "category": "company",
                "datetime": 1782746520,
                "headline": "ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases"
              },
              {
                "id": 140764006,
                "url": "https://finnhub.io/api/news?id=3f07ad9a2f52bce706399ea4a01129692cc29cba98bc12d2a4c2d2a9a6d553e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?",
                "category": "company",
                "datetime": 1782746460,
                "headline": "Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today"
              },
              {
                "id": 140764007,
                "url": "https://finnhub.io/api/news?id=d6612ab429278187759f48a2f17880f404f0cfaff31b14d7d23d55598844fa5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.",
                "category": "company",
                "datetime": 1782746220,
                "headline": "SYRE and Spyre Ride New IBD Trends in Biotech Drug Design"
              },
              {
                "id": 140764008,
                "url": "https://finnhub.io/api/news?id=b03537294713cb377c545bfb6f72f50a370e86973b1edaf8df48c0ca5248058e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data?",
                "category": "company",
                "datetime": 1782746160,
                "headline": "Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts"
              },
              {
                "id": 140763996,
                "url": "https://finnhub.io/api/news?id=f241264e1ae813d3d1334adca34d4c30f747d2ac81b88d7e5865f733236d5d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs"
              },
              {
                "id": 140762577,
                "url": "https://finnhub.io/api/news?id=704ac82083b2d988e51f79da25f2c1b261cdb821a2d54349810ae06cc2cad475",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
                "category": "company",
                "datetime": 1782742740,
                "headline": "AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?"
              },
              {
                "id": 140762578,
                "url": "https://finnhub.io/api/news?id=7c28a23678b91f99ba7e6d7d39fb54fa79fd9554d825c03e2e162eeb3032f54a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
                "category": "company",
                "datetime": 1782741735,
                "headline": "2 S&P 500 Stocks with Promising Prospects and 1 We Find Risky"
              },
              {
                "id": 140762552,
                "url": "https://finnhub.io/api/news?id=388fcf6dadc86ecd1512d77453adb904d121387200cd730d5085356763d5d64f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.",
                "category": "company",
                "datetime": 1782739620,
                "headline": "Here's Why Shares of Eli Lilly Hit an All-Time High on Friday"
              },
              {
                "id": 140768191,
                "url": "https://finnhub.io/api/news?id=5b4d85290ec1e36b8f1a98db9f1fa84bad2c6728327180615fe098467bdafe8e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/29/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and alopecia. Read the latest updates.",
                "category": "company",
                "datetime": 1782738284,
                "headline": "AbbVie Extends Reach Across Dermatology Markets With Dual Regulatory Wins"
              },
              {
                "id": 140760823,
                "url": "https://finnhub.io/api/news?id=de5a4f1daabaad7186e0dbc8b79f5d5aa3b973d71c4b083d869b6ba0b4dfb864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. REGENXBIO will receive $100 million from AbbVie for this milestone.",
                "category": "company",
                "datetime": 1782731100,
                "headline": "REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone"
              },
              {
                "id": 140759892,
                "url": "https://finnhub.io/api/news?id=875c5b3ed3278c90f81fc48bc96d0e4d4bca2c63008a94771cab6900d0004348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.",
                "category": "company",
                "datetime": 1782717000,
                "headline": "AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata"
              },
              {
                "id": 140759893,
                "url": "https://finnhub.io/api/news?id=ffe1a78ba4f346a013bf70277dc95f4258d9ff25cf92612bda6aeb5016ef02ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili",
                "category": "company",
                "datetime": 1782716400,
                "headline": "AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo"
              },
              {
                "id": 140768192,
                "url": "https://finnhub.io/api/news?id=878732a3778324ec7196f14563d0cdbf8f30c436f72245380118d2a22b767d43",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune",
                "category": "company",
                "datetime": 1782702608,
                "headline": "AbbVie's Upadacitinib RINVOQ Receives Positive CHMP Opinion For Non-Segmental Vitiligo, Expected To Be First Systemic Medication For Condition"
              },
              {
                "id": 140755132,
                "url": "https://finnhub.io/api/news?id=5ddfad1581eb9f0fa2d9afa38ae320153b325d400aa0371dd8d4363c15b62fba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]",
                "category": "company",
                "datetime": 1782655279,
                "headline": "RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why"
              },
              {
                "id": 140753794,
                "url": "https://finnhub.io/api/news?id=0238dbfa529ff0ac9ae91a08565d204cdfadb6cfc3fad1f6ffe87f00ecd4fbce",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255413167/image_2255413167.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.",
                "category": "company",
                "datetime": 1782636300,
                "headline": "Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing"
              },
              {
                "id": 140750595,
                "url": "https://finnhub.io/api/news?id=9c89461dd776e2f324612b59652ad3fc2fb4e88b753218deccf070dee9190121",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]",
                "category": "company",
                "datetime": 1782605236,
                "headline": "AbbVie (ABBV) Wins Health Canada Approval for Boey"
              },
              {
                "id": 140748181,
                "url": "https://finnhub.io/api/news?id=1afa664730c817b22844210b73b70f96702fc013903a9f5957595d1a649c57f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]",
                "category": "company",
                "datetime": 1782588099,
                "headline": "AbbVie (ABBV) to Acquire Apogee Therapeutics"
              },
              {
                "id": 140748182,
                "url": "https://finnhub.io/api/news?id=6163d0c8be0ea8a1acd92784ff4e6695081d65544771fddcb031a9248b2c100d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "It has been a banner year for biotech buyouts, and these are two of the prime targets.",
                "category": "company",
                "datetime": 1782583500,
                "headline": "2 Biotech Stocks Worth Buying Before Their Potential Buyouts"
              },
              {
                "id": 140744963,
                "url": "https://finnhub.io/api/news?id=d502d3e234636610a86a46fb082cae7d5af2639e1594755baf12d54b8bc8d7f9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.",
                "category": "company",
                "datetime": 1782541720,
                "headline": "Best Dividend Aristocrats: June 2026"
              },
              {
                "id": 140746818,
                "url": "https://finnhub.io/api/news?id=ccf8f75c2b2b802f106da65a31a7b2a44c9a05d7677a63d82f30c5ac54bb15a1",
                "image": "https://image.cnbcfm.com/api/v1/image/108327370-1782479095800-gettyimages-2282258494-AFP_B7WQ8LJ.jpeg?v=1782479203&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "Temperature records were smashed across Europe this week, prompting several countries across the continent to issued high-level warnings about danger to life.",
                "category": "company",
                "datetime": 1782522002,
                "headline": "Red-alert heatwaves are becoming Europe's new normal. Investors are paying attention"
              },
              {
                "id": 140742959,
                "url": "https://finnhub.io/api/news?id=1c05d80b484fc80f4edac27600c8ac2915fb138233bca6ec9ce42d41a131bb3d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2264695653/image_2264695653.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Micron delivered a blowout quarter & reinforced strength of AI-driven memory demand, but same surge in memory prices pressured Apple, Microsoft, Amazon & other mega-cap technology names.",
                "category": "company",
                "datetime": 1782516900,
                "headline": "This Week's Market Wrap: AI Memory Shock, Crude Cracks, And Data Boxes In The Fed"
              },
              {
                "id": 140740449,
                "url": "https://finnhub.io/api/news?id=f6a988795409af94717de53f073294a852fcf0e4bbcc18e1709c1309112b06a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available 150 mg PFS and Pen are approved",
                "category": "company",
                "datetime": 1782507000,
                "headline": "SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease"
              },
              {
                "id": 140737991,
                "url": "https://finnhub.io/api/news?id=4f1f92e9bfd556033ca1e9a7a947069be8194bd99d29c4f03bd80a254adeb6e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Lilly, AbbVie and J&J extend winning streaks.",
                "category": "company",
                "datetime": 1782496164,
                "headline": "Lilly, J&J and AbbVie Hit New Highs"
              },
              {
                "id": 140746796,
                "url": "https://finnhub.io/api/news?id=fe15595f4953f27cc4b58c74d5c83ff2d2864a24e30ace17bb82dd2bdc1827df",
                "image": "https://image.cnbcfm.com/api/v1/image/108327725-17825072231782507209-46792477115-1080pnbcnews.jpg?v=1782507222&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.",
                "category": "company",
                "datetime": 1782493286,
                "headline": "Why BMO's Siegerman says Merck is a top healthcare stock pick"
              },
              {
                "id": 140748304,
                "url": "https://finnhub.io/api/news?id=d1d962d19509739231c1eb67fc28a928f049a72ddc27049ac95886aaf13f5740",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis",
                "category": "company",
                "datetime": 1782492886,
                "headline": "AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis"
              },
              {
                "id": 140737993,
                "url": "https://finnhub.io/api/news?id=4ec7a0224ab0405979874fb3b438152890cd9bb8fada3b210159c9b7b2acaaad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.",
                "category": "company",
                "datetime": 1782489808,
                "headline": "AbbVie Stock's Growth Story Has One Question Mark"
              },
              {
                "id": 140738757,
                "url": "https://finnhub.io/api/news?id=d58fd80f49e9e0925cf231b4dca09e8d6e01cfe9cda871ac3a7da83a8eb416a4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/26/benzinga-deal-dispatch2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy's Gourmet Bakery.",
                "category": "company",
                "datetime": 1782481965,
                "headline": "Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy"
              },
              {
                "id": 140735299,
                "url": "https://finnhub.io/api/news?id=5fe7bf3e337199b0122e308217346945ded049af6d4e16b8e6dab4fed0a9954c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
                "category": "company",
                "datetime": 1782475200,
                "headline": "AbbVie to Host Second-Quarter 2026 Earnings Conference Call"
              },
              {
                "id": 140734587,
                "url": "https://finnhub.io/api/news?id=2d98039cb3da14d27d9d41d10e99ef9a40ddd94d6f9fb53b22637de6537c633f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "What does retirement look like for someone who genuinely has no desire to leave home? No snowbird condo in Florida. No Viking river cruises. No RV parked outside Yellowstone. Just Chicago. The Cubs in the summer, the museums when the weather turns, dinner at the neighborhood Italian restaurant, church on Sunday, and grandchildren across town ... The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?",
                "category": "company",
                "datetime": 1782471818,
                "headline": "The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?"
              },
              {
                "id": 140735129,
                "url": "https://finnhub.io/api/news?id=8f1bf596ce182e56e350eee0da5f22dee126d24c8d2f65b0f0da933c699ddae7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260722103/image_2260722103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Jazz Pharmaceuticals' shares are in the distribution phase because Zepzelca failed to show a survival benefit over irinotecan. See why JAZZ stock is downgraded to hold.",
                "category": "company",
                "datetime": 1782465751,
                "headline": "Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)"
              },
              {
                "id": 140734826,
                "url": "https://finnhub.io/api/news?id=1ce712a5688b7722bcbeb5e96cb58f3f49f734ded6c6a16531f54f12425fea83",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193247114/image_2193247114.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Stocks with above-average dividend yields often represent mature businesses with resilient earnings and disciplined management. Read more here.",
                "category": "company",
                "datetime": 1782462000,
                "headline": "High Income Outpaces Mega-Cap Tech In Return/Risk Terms"
              },
              {
                "id": 140731244,
                "url": "https://finnhub.io/api/news?id=b65f11a660667b59ab48ab768a7a13923dcf3b1cee4365a8ac72e988b96ea232",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Earlier this week, AbbVie reported European Commission approvals extending Skyrizi to children with moderate to severe plaque psoriasis and making Maviret the only therapy cleared in the EU for both acute and chronic hepatitis C infection from age three. These label expansions broaden AbbVie’s reach in immunology and virology by opening earlier treatment windows and adding pediatric populations in high-need diseases. We’ll now explore how Skyrizi’s new pediatric indication and Maviret’s...",
                "category": "company",
                "datetime": 1782436235,
                "headline": "Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?"
              },
              {
                "id": 140729431,
                "url": "https://finnhub.io/api/news?id=a39ed9ec0df153be4a5560c97317f1cb46625a61f77315297ea5701c0fb1f3d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.",
                "category": "company",
                "datetime": 1782422101,
                "headline": "AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140737450,
                "url": "https://finnhub.io/api/news?id=647526d9eaff5708330f9872a6264ce8a5067d661cc27a4dce2c6fee73926720",
                "image": "https://image.cnbcfm.com/api/v1/image/108327432-1782483970820-Traders-Photo-20260626-KK-PRESS-001.jpg?v=1782484337&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "OpenAI is reportedly considering delaying its IPO and as a sell-off in tech gathered pace.",
                "category": "company",
                "datetime": 1782410579,
                "headline": "S&P 500 heads for losing week, chip stocks add to their losses on Friday: Live updates"
              },
              {
                "id": 140727404,
                "url": "https://finnhub.io/api/news?id=06fab829fe62c2436d2a79a773b56cea23e15ff70c7b6d8db2dcecd49b6a04cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Formula Wellness, a leader in integrated longevity and aesthetic medicine, announced that it has earned Top 50 Status for 2026 from Allergan Aesthetics, an AbbVie company and the makers of Botox®. The recognition honors Formula Wellness's ongoing commitment to the Allergan Aesthetics portfolio and places the practice among the program's highest-performing partners, reflecting a year of rapid growth as one of the fastest-growing integrated wellness and aesthetics platforms in the U.S.",
                "category": "company",
                "datetime": 1782402900,
                "headline": "Formula Wellness Earns Top 50 Status for 2026 from Allergan Aesthetics"
              },
              {
                "id": 140725695,
                "url": "https://finnhub.io/api/news?id=e2899f4a6a0a91be4296b63f3eda7463dcbde12ee2dcde2929bee0f7bb3c3a04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?",
                "category": "company",
                "datetime": 1782396780,
                "headline": "Is AbbVie a Buy After Its Purchase of Apogee?"
              },
              {
                "id": 140724606,
                "url": "https://finnhub.io/api/news?id=0d1961ad9d71d6b4eff1b068ae2c5f9759a78f397cdb9774d6ea8f743fab0316",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.",
                "category": "company",
                "datetime": 1782389712,
                "headline": "3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree"
              },
              {
                "id": 140721322,
                "url": "https://finnhub.io/api/news?id=11cf5f2b6926e5e69118757b5a755b4555288298b79c7ad185155a93a75735e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is included among the Top 10 Blue Chip Stocks with Growing Dividends. On June 23, Canaccord raised its price recommendation on AbbVie Inc. (NYSE:ABBV) to $273 from $265. It reiterated a Buy rating on the shares. The firm updated its model following AbbVie’s announced acquisition of Apogee Therapeutics (APGE). Canaccord said the […]",
                "category": "company",
                "datetime": 1782358501,
                "headline": "Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook"
              },
              {
                "id": 140718240,
                "url": "https://finnhub.io/api/news?id=df2aa622c374d493d43c87ea6b5c1b9372525206ed334faa510a62f2a81c1195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "I hit the buy button on AbbVie (NYSE:ABBV) again last week, and I will hit it again the next time June’s macro noise hands me a discount. While short-term traders chase headlines around sticky 4.2% inflation and a softening jobs picture, I keep adding shares of a cash machine that does not care which way ... Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut",
                "category": "company",
                "datetime": 1782333210,
                "headline": "Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut"
              },
              {
                "id": 140717005,
                "url": "https://finnhub.io/api/news?id=3f59a4c983b77042aa9b5c7b418ca5680832404b8328b939e755f4f4f4ef0e61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.",
                "category": "company",
                "datetime": 1782329550,
                "headline": "The Number That Could Test AbbVie Stock"
              },
              {
                "id": 140717033,
                "url": "https://finnhub.io/api/news?id=9c93a9c9a284f35ff781754795f02229b9e6abc0a3e3f9c7bdf3b2cda0648adf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a",
                "category": "company",
                "datetime": 1782324900,
                "headline": "VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development"
              },
              {
                "id": 140713888,
                "url": "https://finnhub.io/api/news?id=e8c5b55cc2a57a61675e324a63c50cb4d36a58cabb11d6e36933d5879257cd55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Most retirees shop for dividend portfolios the same way people shop for cars: they focus on what they get today. A portfolio yielding $90,000 a year feels like the retirement equivalent of driving a Ferrari off the lot. Another portfolio paying only $45,000 can look more like a dependable Honda. The mistake is assuming the race ... The Dividend Portfolio That Starts Like A Honda And Ends Like A Ferrari",
                "category": "company",
                "datetime": 1782315531,
                "headline": "The Dividend Portfolio That Starts Like A Honda And Ends Like A Ferrari"
              },
              {
                "id": 140714022,
                "url": "https://finnhub.io/api/news?id=85dace0a37b182e9bfd563090daeb85e2ec7803cddda2770b4197fce610efda8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at 4.50% and the 30-year at 4.94%, dividend yields have to earn their seat. The 10-year has swung between 4.43% and 4.56% in June alone, and that yield volatility is exactly what forced me to re-stack ... 64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital",
                "category": "company",
                "datetime": 1782309744,
                "headline": "64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital"
              },
              {
                "id": 140714023,
                "url": "https://finnhub.io/api/news?id=7a6e661d5141f78e659cfcc9463326cc66cbb22d75f8417b1a3730e31dc22fc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV gains EU approval for Skyrizi in pediatric plaque psoriasis, expanding reach in younger patients with a new weight-based dosing option.",
                "category": "company",
                "datetime": 1782307920,
                "headline": "AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis"
              },
              {
                "id": 140714024,
                "url": "https://finnhub.io/api/news?id=16ec6bad57994bea6c1ec48b3f27408e551c3834aac7de078d5931a081967155",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782306780,
                "headline": "Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?"
              },
              {
                "id": 140712865,
                "url": "https://finnhub.io/api/news?id=5bcc778f6e2bf2742bd05456d20704362f4ad86af4d0f602ad7b81ca1751d419",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2026 cohort of entrepreneurs selected to participate in The Confidence Collective: Empowering Women Entrepreneurs, an ongoing initiative from BOTOX® Cosmetic dedicated to uplifting and investing in women businessowners.",
                "category": "company",
                "datetime": 1782302400,
                "headline": "BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026"
              },
              {
                "id": 140712849,
                "url": "https://finnhub.io/api/news?id=fcee63194768ef646b8c0bbdf656e0492431a97d6dc5779ab4a0eea43cbe7094",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in its business and a share price that looks like a mistake.",
                "category": "company",
                "datetime": 1782302110,
                "headline": "After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching"
              },
              {
                "id": 140717456,
                "url": "https://finnhub.io/api/news?id=16629f73061734723fc630518f4984dfbd29b830e9b581ec4b95095fcc829670",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.21% on an annualized basis producing an average annual return of 15.79%. Currently, AbbVie has a market capitalization of $417.60 billion.",
                "category": "company",
                "datetime": 1782301564,
                "headline": "Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years"
              },
              {
                "id": 140712191,
                "url": "https://finnhub.io/api/news?id=6c111b38ecd53627bceba5cbefed96f434053d654af58b66e5a576ec640925f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
                "category": "company",
                "datetime": 1782296665,
                "headline": "2 Value Stocks Worth Your Attention and 1 Facing Headwinds"
              },
              {
                "id": 140712192,
                "url": "https://finnhub.io/api/news?id=ee6d45a1b38fc019d57eee2e18b70ae66f2261fe0636cda4db1069d9c75b5661",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie’s model fair value is held at US$253.55 per share, signaling no change to the core price target after factoring in the proposed Apogee Therapeutics acquisition. Research around the US$10.9b deal points to a split view, with some analysts highlighting the immunology and atopic dermatitis opportunity, while others question how much value the company can capture against rising competition. As you read on, you will see how these mixed signals are shaping the evolving AbbVie story and what...",
                "category": "company",
                "datetime": 1782296109,
                "headline": "AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal"
              },
              {
                "id": 140709049,
                "url": "https://finnhub.io/api/news?id=730aac618736f73923a256a5484b639aae898ab0da37051ef3cd0e3ec992cdba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Lilly's expected global sales of $137 billion in 2032 will be driven by its weight-loss drugs.",
                "category": "company",
                "datetime": 1782254183,
                "headline": "Thinking Thin Pays Off: Lilly To Dominate Pharma World By 2032"
              },
              {
                "id": 140706976,
                "url": "https://finnhub.io/api/news?id=40cea8fb275d861a3becf0bae0ceea497224f2f0a3b6e14fb3a81a0e9b67bd1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.",
                "category": "company",
                "datetime": 1782244632,
                "headline": "The $50B Plan Merck Stock Was Broadcasting"
              },
              {
                "id": 140705613,
                "url": "https://finnhub.io/api/news?id=dacb874b40001fae147568e753562394b2ecc01221640017e808e3754fad2459",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St",
                "category": "company",
                "datetime": 1782243964,
                "headline": "Sector Update: Healthcare Stocks Higher Late Afternoon"
              },
              {
                "id": 140709053,
                "url": "https://finnhub.io/api/news?id=5ecdac3d072f9bb25d831165de2d9d2e15b5b5d5335c462b022e9e243c64d12d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.",
                "category": "company",
                "datetime": 1782242155,
                "headline": "AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors."
              },
              {
                "id": 140705489,
                "url": "https://finnhub.io/api/news?id=d2c0a881e118530f7d04d269c30247f43c6ab0fd676ae385ceb6053834b84ed8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "By selecting high-quality stocks with above-average yields, the iShares Core High Dividend ETF generates sustainable income.",
                "category": "company",
                "datetime": 1782238920,
                "headline": "Here's How Much You'd Need to Invest in HDV to Generate $500 per Month in Dividends"
              },
              {
                "id": 140704866,
                "url": "https://finnhub.io/api/news?id=6a016defe1b9dc53f0a16467941078ed767221dc5a1d439272f088d00e57048c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222145/image_2194222145.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "After lagging expectations during recent market volatility, the healthcare sector is showing signs of strength. TD Asset Management's Jacky He explains what's driving the sector’s rebound.",
                "category": "company",
                "datetime": 1782226200,
                "headline": "Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities"
              },
              {
                "id": 140702554,
                "url": "https://finnhub.io/api/news?id=5e103ccd28860e23a8e1908842ed8acff7a828e65123b3b3b799efea6574db45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.",
                "category": "company",
                "datetime": 1782226200,
                "headline": "ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout"
              },
              {
                "id": 140702525,
                "url": "https://finnhub.io/api/news?id=5bf5a44551601524b50a049b88699f5112e9aee3d8f1facbb2f8398bfe9f12f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.",
                "category": "company",
                "datetime": 1782222600,
                "headline": "Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?"
              },
              {
                "id": 140702492,
                "url": "https://finnhub.io/api/news?id=9410f4dfe0704c561022e4695b5da1f5971aa0caa2f492850585bad2aebbf6a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Companies in The News Are: APGE, ABBV, DLR, META, SNDK",
                "category": "company",
                "datetime": 1782221100,
                "headline": "Company News for Jun 23, 2026"
              },
              {
                "id": 140705019,
                "url": "https://finnhub.io/api/news?id=b37d46cce695b185bc228942546a797aa15633833ae5dd305cf31c637248b80a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/23/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.",
                "category": "company",
                "datetime": 1782220276,
                "headline": "AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst"
              },
              {
                "id": 140701458,
                "url": "https://finnhub.io/api/news?id=a302b805cffe3555f881a568aba0b89e9bed806ed1241863513860dee0de8f41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "European Commission Expands Skyrizi Label to Younger PatientsAbbVie (NYSE:ABBV) has received approval from the European Commission to use Skyrizi (risankizumab) in children and adolescents aged six years and older with moderate-to-severe plaque psoriasis who are eligible for systemic treatment. The authorization broadens the medicine’s reach within Europe and provides a new treatment option for younger patients living with the chronic inflammatory skin condition.",
                "category": "company",
                "datetime": 1782218709,
                "headline": "AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV)"
              },
              {
                "id": 140701432,
                "url": "https://finnhub.io/api/news?id=18f1e4cfd0598feca125bcf022d603484177055aad67802d5c5e9c2b913ef1ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.",
                "category": "company",
                "datetime": 1782217249,
                "headline": "Should You Buy Or Sell AbbVie Stock At $230?"
              },
              {
                "id": 140703196,
                "url": "https://finnhub.io/api/news?id=031ad4136d864a64152f49999406d55753bbc25932ff6883f89e758ee9e63ae2",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Piper Sandler  analyst David Amsellem   reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $298 price target.",
                "category": "company",
                "datetime": 1782217185,
                "headline": "Piper Sandler Reiterates Overweight on AbbVie, Maintains $298 Price Target"
              },
              {
                "id": 140701460,
                "url": "https://finnhub.io/api/news?id=1f4d8963e663043d130ebdbb8bf89d6dbef3a6cf75370462d5bba19bf64c6dbd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced Health Canada has approved Boey® (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe lines between the eyebrows (glabellar lines) in adult patients.",
                "category": "company",
                "datetime": 1782216000,
                "headline": "Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients"
              },
              {
                "id": 140701461,
                "url": "https://finnhub.io/api/news?id=43fb372aebb93f4d3dbfe3b8e536eb705ffd9e3979ce2e04c52c4313c9a44d80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next? The Apogee setup is the template buyers are chasing: late-stage clinical data, a meaningful addressable market, ... 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal",
                "category": "company",
                "datetime": 1782215741,
                "headline": "3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal"
              },
              {
                "id": 140703197,
                "url": "https://finnhub.io/api/news?id=9398d0161c40bb54db9f1f3b1fd8fb53eca2d46a436eaca710ea7e74b1d889da",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Canaccord Genuity  analyst Gary Nachman   maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $265 to $273.",
                "category": "company",
                "datetime": 1782208847,
                "headline": "Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $273"
              },
              {
                "id": 140700230,
                "url": "https://finnhub.io/api/news?id=17e54ba1f429590d0cf12c644101d6fedd8ed0ea6bad3dad2a87e94432168baa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "WATERTOWN, Mass., June 23, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older. M",
                "category": "company",
                "datetime": 1782205800,
                "headline": "Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus"
              },
              {
                "id": 140700231,
                "url": "https://finnhub.io/api/news?id=3c638dd51d447379d18adb655208a9c4cee32dd89f0bfc9717dda7bc4b3162d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged 3 years and older. With this approval, MAVIRET is now the only treatment approved in the European Union for both acute and chronic HCV infection.",
                "category": "company",
                "datetime": 1782205200,
                "headline": "AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection"
              },
              {
                "id": 140699741,
                "url": "https://finnhub.io/api/news?id=9981257b662613b58d2f92a94b6ad8c76080b4ff2f4eacd02a82440a2a26b660",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe (PFS) to support weight-based dosing for patients weighing less than 40 kg.1",
                "category": "company",
                "datetime": 1782198000,
                "headline": "AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis"
              },
              {
                "id": 140700071,
                "url": "https://finnhub.io/api/news?id=c0b83a5ff4f2e5ef491430e7fcb725707dd1fae765d0cee98d2415b0f56a42c3",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "2026-06-23. The following slide deck was published by AbbVie Inc.",
                "category": "company",
                "datetime": 1782192665,
                "headline": "AbbVie Inc. (ABBV) Apogee Therapeutics, Inc. - M&A Call - Slideshow"
              },
              {
                "id": 140703198,
                "url": "https://finnhub.io/api/news?id=22757b4a0da58e161162c1dca8d9990d883c3ec08854d5869f436d336d461c49",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "MAVIRET (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children",
                "category": "company",
                "datetime": 1782191323,
                "headline": "AbbVie's MAVIRET Approved By European Commission For Acute HCV Infection, Becomes Only EU-Approved Treatment For Both Acute And Chronic Hepatitis C Virus Infection"
              },
              {
                "id": 140699192,
                "url": "https://finnhub.io/api/news?id=10f7b56e43fcba0d90b045d62f3a1992fd92c405874f52b17d9f838fde0d1cef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "With a 5-Year Average Dividend Growth Rate of 6.33%, AbbVie Inc. (NYSE:ABBV) is included among the Top 11 Dividend Kings to Buy for Safe Dividend Growth. On June 22, Wells Fargo maintained an Overweight rating on AbbVie Inc. (NYSE:ABBV). It also set a $260 price target on the shares. The firm said AbbVie’s reported bid […]",
                "category": "company",
                "datetime": 1782189676,
                "headline": "Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee Acquisition"
              },
              {
                "id": 140698594,
                "url": "https://finnhub.io/api/news?id=a58b2989a97ca0de21cea48638499bbb2bb193d00a44f55c9283dfc09bb0b4f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.",
                "category": "company",
                "datetime": 1782184692,
                "headline": "Why AbbVie Stock Jumped Today"
              },
              {
                "id": 140703199,
                "url": "https://finnhub.io/api/news?id=deefb2cc81b50730c3dd9fa553bef1ef96e25009d4ef6ba9130fda961d891a78",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "SKYRIZI (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasisApproval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials",
                "category": "company",
                "datetime": 1782183893,
                "headline": "AbbVie Says European Commission Approves SKYRIZI For Children And Adolescents Six Years And Older With Moderate To Severe Plaque Psoriasis"
              },
              {
                "id": 140698626,
                "url": "https://finnhub.io/api/news?id=bf08b3fdf7fe896457c8d83c29ab2e468d6620439245588b0e6099712186d6c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The gains showed increasing investor interest in companies benefiting from rising demand for AI infrastructure, large-scale chip manufacturing projects, and acquisitions.",
                "category": "company",
                "datetime": 1782183855,
                "headline": "Why Did INTC, KEEL, APGE Stocks Hit 52-Week Highs Today?"
              },
              {
                "id": 140698052,
                "url": "https://finnhub.io/api/news?id=b20d297a18068e61303650d8b721c8eaf6a2720d497d4c9449161dd174c7bb24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 Stocks Paying Off Big Time. Apogee Therapeutics soared to a fresh all-time high on Monday, as investors gobbled up shares following announcements that it is set to be acquired by pharmaceutical giant AbbVie Inc. at a 49 percent premium. In a joint statement on the same […]",
                "category": "company",
                "datetime": 1782179630,
                "headline": "Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger"
              },
              {
                "id": 140697312,
                "url": "https://finnhub.io/api/news?id=5025fdbe50dceaa6b277d75e83f34b398fa8014a3bc625dd6bcd350a5f33809a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company is already renowned by many as a giant in the segment.",
                "category": "company",
                "datetime": 1782168984,
                "headline": "AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?"
              },
              {
                "id": 140697392,
                "url": "https://finnhub.io/api/news?id=f8836eb6769871a5d5d72393dc9572772ba6c1b8a75d292b4b05b4bce7b9b1da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.",
                "category": "company",
                "datetime": 1782166464,
                "headline": "Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer"
              },
              {
                "id": 140698634,
                "url": "https://finnhub.io/api/news?id=8a4408e78a2019d50517724c94a6ad06b90dc38cf162a54dcace3b555b03309a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.",
                "category": "company",
                "datetime": 1782161616,
                "headline": "The $11 Billion Reason Abbvie Stock Is Up Today"
              },
              {
                "id": 140694965,
                "url": "https://finnhub.io/api/news?id=d3ac72655402a115d029654e212e81e7532e8336432523a611ecec2f46a1d0ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Updates with index/price moves and political news from the first paragraph.) US equity indexes t",
                "category": "company",
                "datetime": 1782157809,
                "headline": "Update: US Equity Indexes Mixed as Communication Services Sector Slides, Treasury Yields Surge"
              },
              {
                "id": 140694981,
                "url": "https://finnhub.io/api/news?id=0b8334e607f0562ba1af8ce935a6870dff56965f446c93148d2bf2dab4ae887b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Yahoo Finance Senior Reporter Brooke DiPalma joins Josh Lipton in highlighting the day's biggest stories and stock moves, including AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE) and Coca-Cola's (KO) latest legal showdown with the IRS in US appeals court.",
                "category": "company",
                "datetime": 1782157639,
                "headline": "Abbvie acquiring Apogee for $10.9B, Coca-Cola vs. IRS in appeals court"
              },
              {
                "id": 140695040,
                "url": "https://finnhub.io/api/news?id=0a5cbd73e245055812f02774282d78ba7bc8d60b716216b950cfc82e49829c36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.9% and",
                "category": "company",
                "datetime": 1782157407,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 140694636,
                "url": "https://finnhub.io/api/news?id=ebc9b2b902d4d057f0b7586981632024e503d45a65eef814196e69484a8477d2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1782155101,
                "headline": "Monday's session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 140695041,
                "url": "https://finnhub.io/api/news?id=e458f2d242ac4d633c887788f2406699f1cc9bb97d6bcf4b41f7c3c3020c73cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The $135.11 per share cash offer for Apogee carries a 49% premium",
                "category": "company",
                "datetime": 1782154761,
                "headline": "AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree"
              },
              {
                "id": 140695042,
                "url": "https://finnhub.io/api/news?id=d720f9fc2263c81e496e1e0848e7dbc884099f708a234bd8e66e7170229340fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Updates with latest market prices and developments.) US benchmark equity indexes were mixed intr",
                "category": "company",
                "datetime": 1782151886,
                "headline": "Update: Equities Mixed Intraday, Oil Falls as US-Iran Talks Advance"
              },
              {
                "id": 140695043,
                "url": "https://finnhub.io/api/news?id=1bfbf4a75599d6ba79960014a02b1204dd7a53e503923d24cbc2756183348410",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engageme",
                "category": "company",
                "datetime": 1782151648,
                "headline": "Top Midday Gainers"
              },
              {
                "id": 140694926,
                "url": "https://finnhub.io/api/news?id=3c23eb523a69aec8d92fb418672f2fe93473972b9c725dce57db37acffc3c731",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Updates with index/price moves and political/company news from the first paragraph.) US equity i",
                "category": "company",
                "datetime": 1782151475,
                "headline": "Update: US Equity Indexes Mixed Amid Steep Decline in Communication Services, Surging Treasury Yields"
              },
              {
                "id": 140695735,
                "url": "https://finnhub.io/api/news?id=eb643e9b369c6f1ca3d95918b5f6dde46c96ecb1b0d803cc550971791ff035fa",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie Inc. (ABBV) M&A Call June 22, 2026 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert Michael -...",
                "category": "company",
                "datetime": 1782147729,
                "headline": "AbbVie Inc. (ABBV) M&A Call Transcript"
              },
              {
                "id": 140693164,
                "url": "https://finnhub.io/api/news?id=9716d304d8d5fc6ad9cba15f039e7587e1847e0df5146ae9751bb12b4f8ca5ba",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1782146100,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 140693823,
                "url": "https://finnhub.io/api/news?id=98cf4c5fbebaa35e052299342c37d4d460643cc6257fb99db83c2cca759fc137",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has agreed to acquire Apogee Therapeutics in a cash deal valued at US$10.9b. The transaction focuses on expanding AbbVie's immunology and respiratory disease pipeline with several clinical-stage candidates. The deal is described as AbbVie's largest acquisition in more than five years and includes a premium to Apogee's recent trading levels. AbbVie is a large biopharmaceutical company with a long-standing focus on immunology, oncology, neuroscience, and other specialty...",
                "category": "company",
                "datetime": 1782144805,
                "headline": "AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion"
              },
              {
                "id": 140692413,
                "url": "https://finnhub.io/api/news?id=cf927366051b9be9de10bf2c924b9159fd7dfd9f13e751998bfbc6ad17403758",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The Nasdaq Composite and S&P 500 were down, while the Dow Jones Industrial Average was up in late-mo",
                "category": "company",
                "datetime": 1782143421,
                "headline": "Top Midday Stories: Treasury Authorizes Sale of Iranian Oil; SpaceX launches First Inaugural Bond Issuance"
              },
              {
                "id": 140694912,
                "url": "https://finnhub.io/api/news?id=db03dba06177b3713b65c87a616cd657a9941fbc91f2ea780de247110fae4f58",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2282581949/image_2282581949.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Apogee Therapeutics is being acquired by AbbVie for $135.11 per share in cash, capping further upside. Click here to read my most recent analysis of APGE.",
                "category": "company",
                "datetime": 1782143216,
                "headline": "Apogee: 'Hold' On AbbVie $10.9B Buyout And Extended Half-Life IL-13 Zumilokibart For AD"
              },
              {
                "id": 140692564,
                "url": "https://finnhub.io/api/news?id=4746f621666d98e3a6d40919960793419ab223be51adb370c274d214774b06f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1782142811,
                "headline": "Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing"
              },
              {
                "id": 140692565,
                "url": "https://finnhub.io/api/news?id=d99882d461e0301ae3a8edfc2c101b5dd5d87562eae8e8a5e0cf0d0d00d42f6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The multi-billion-dollar bid could further cement AbbVie’s leading position in the immunology space as competition heats up.",
                "category": "company",
                "datetime": 1782142408,
                "headline": "AbbVie deepens immunology legacy in $10.9bn Apogee buyout"
              },
              {
                "id": 140692566,
                "url": "https://finnhub.io/api/news?id=ea74d2f08ef061bf4354e0071247f6161814750e73a4924c3c98a5e0640b9362",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn't need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO.",
                "category": "company",
                "datetime": 1782141170,
                "headline": "AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers"
              },
              {
                "id": 140694513,
                "url": "https://finnhub.io/api/news?id=bf4ff48ec3ff894ead82fedf5066192cdb2872503761b4fb236b55129f2899e3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2228921995/image_2228921995.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie Inc.’s $10.9B Apogee Therapeutics, Inc. buyout boosts its immunology pipeline with APG777 for atopic dermatitis. Click for this ABBV stock update.",
                "category": "company",
                "datetime": 1782140627,
                "headline": "AbbVie: Why The Pharma Wins Twice With Its Apogee Acquisition"
              },
              {
                "id": 140694468,
                "url": "https://finnhub.io/api/news?id=19875c26d5a44b28cb4f468725092a6adf1907c9fb72d9c0d14cf82e4e509b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2265639604/image_2265639604.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Stocks retract, U.S. authorizes Iranian oil sales. Options flashing growing concern and Micron partners with Anthropic.",
                "category": "company",
                "datetime": 1782139800,
                "headline": "Wall Street Lunch: U.S. Authorizes Iranian Oil Sales"
              },
              {
                "id": 140692527,
                "url": "https://finnhub.io/api/news?id=52cff7ec1098ae14406a3080b9e86f2a3739519ce6c8c3378d3ce8cb40cc2eb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.",
                "category": "company",
                "datetime": 1782139584,
                "headline": "Merck Stock’s New Drugs Were Already Answering The Big Question"
              },
              {
                "id": 140692528,
                "url": "https://finnhub.io/api/news?id=9ce755bfa4501e13378d6ba3b118cd90843a60144c19398dc04f4a209b9cccd0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.",
                "category": "company",
                "datetime": 1782138180,
                "headline": "Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics"
              },
              {
                "id": 140692569,
                "url": "https://finnhub.io/api/news?id=9002d62a8bcf577bf8200935d804c61f6bae402bcdcbb43d1414ba482169186f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Under...",
                "category": "company",
                "datetime": 1782137040,
                "headline": "AbbVie to acquire Apogee Therapeutics in $10.9B deal"
              },
              {
                "id": 140692529,
                "url": "https://finnhub.io/api/news?id=eeb880e0e03e6642499b51bf973887d5bc7190d2f207cc6898bd9360e56c032b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.",
                "category": "company",
                "datetime": 1782136320,
                "headline": "AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?"
              },
              {
                "id": 140691605,
                "url": "https://finnhub.io/api/news?id=ec6d1b599dc55794abbf6af26231a8f67f8e8338f0b6782eb581023a9352b6e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9",
                "category": "company",
                "datetime": 1782135497,
                "headline": "AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal"
              },
              {
                "id": 140692571,
                "url": "https://finnhub.io/api/news?id=fa11ca6a598f4408616c7eb67e33445ca802c1f24d5d17fac0c26f8ba28b1ed2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.",
                "category": "company",
                "datetime": 1782135300,
                "headline": "Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?"
              },
              {
                "id": 140691606,
                "url": "https://finnhub.io/api/news?id=be32ce68d8ccd3d3417c32d9d5df5c93419735ea5bd5e0c41dc995299f93999d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie announced Monday a $10.9 billion plan to acquire immunology-focused Apogee Therapeutics, sending Apogee stock flying.",
                "category": "company",
                "datetime": 1782134164,
                "headline": "AbbVie Goes On The Offensive With $10.9 Billion Takeover"
              },
              {
                "id": 140691607,
                "url": "https://finnhub.io/api/news?id=d4f4efa5306c8d6c87751580c0b056e04c7b9c3e6f387c117c62bd97208092f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "U.S. stock futures edged higher on Monday as investors monitored corporate dealmaking activity and developments in the biotechnology and cryptocurrency sectors.",
                "category": "company",
                "datetime": 1782133716,
                "headline": "Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal"
              },
              {
                "id": 140693957,
                "url": "https://finnhub.io/api/news?id=aaab00fe0bfbe8c981fb85ca71331be72dcbe6661da315917727d4d151a5739c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/22/Glowing-Red-Stock-Market-Graph-Shows-Dow.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Alphabet sinks 6% on a DeepMind departure as AI names drag the S&P 500 and Nasdaq lower; the Dow and small caps rise.",
                "category": "company",
                "datetime": 1782133307,
                "headline": "Alphabet Tumbles 6%, SpaceX Sinks 10% On Bond Sale: Stock Market Today"
              },
              {
                "id": 140691608,
                "url": "https://finnhub.io/api/news?id=656fbfbad1d274ca13920b5764b41d8691b183d2b659004ef63529f504bdc9f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra",
                "category": "company",
                "datetime": 1782133134,
                "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Amid Continued US-Iran Talks"
              },
              {
                "id": 140691609,
                "url": "https://finnhub.io/api/news?id=8eb434fd3750dd1167f4555868d2eec78dc1972831fed0fe5d00e473a58e2636",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) announced on Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) for $10. 9 billion, marking its largest acquisition in more than five years and reinforcing its commitment to expanding its next-generation immunology pipeline.",
                "category": "company",
                "datetime": 1782133117,
                "headline": "AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV)"
              },
              {
                "id": 140693243,
                "url": "https://finnhub.io/api/news?id=fc5bfdfff8502e56df6a4b37e34133dead06385c8e19c10dfed19fb0a834d5fc",
                "image": "https://image.cnbcfm.com/api/v1/image/108163809-1750859258336-gettyimages-1240744869-SOFIC_2022.jpeg?v=1782148502&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1782133065,
                "headline": "Stocks making the biggest moves midday: Alphabet, AeroVironment, Salesforce, Apogee Therapeutics & more"
              },
              {
                "id": 140691482,
                "url": "https://finnhub.io/api/news?id=70c5e23af3b5822b54aedce84730b1a7069c27f3507f3b012fed29b228a2a436",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "9.55am: Dow up but Nasdaq flat US stocks were showing a familiar split in opening trades, with the Dow Jones opening up 0.5% as investors rotate into cyclical and defensive blue chips including JPMorgan, Goldman Sachs, Caterpillar, UnitedHealth and Amgen. The S&P 500 climbed just over...",
                "category": "company",
                "datetime": 1782132360,
                "headline": "Dow Jones opens higher but Nasdaq flat as hawkish Fed still looms"
              },
              {
                "id": 140691505,
                "url": "https://finnhub.io/api/news?id=7fb6b6afa656cec1fe0bb0120da134cdbca562aa09232c8f9a8045f5a7ddd9a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1782132301,
                "headline": "Update: US Equity Futures Slightly Higher Pre-Bell As US-Iran Talks Start in Switzerland"
              },
              {
                "id": 140691612,
                "url": "https://finnhub.io/api/news?id=a3aefa6bdba58bddf3fbf8a5a95e877962d33708581517fe468444574dea477f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis",
                "category": "company",
                "datetime": 1782131533,
                "headline": "AbbVie acquires Apogee Therapeutics for $10.9 billion"
              },
              {
                "id": 140691567,
                "url": "https://finnhub.io/api/news?id=df41a39fbb26cf91fc65d9248d0c35d5945ae42e2bc0bf16fa03aab53bc9b0fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.",
                "category": "company",
                "datetime": 1782130980,
                "headline": "AbbVie’s $10.9 Billion Apogee Therapeutics Buyout Protects Its Immunology Crown"
              },
              {
                "id": 140693119,
                "url": "https://finnhub.io/api/news?id=813db00faa2e838687517ca9cba35454efa3d99ad387205d335296cc5855fac2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/22/The-Real-Villains-No-Longer-Hide.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC, MLTX, FRVO, and SMCI.",
                "category": "company",
                "datetime": 1782130120,
                "headline": "Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday"
              },
              {
                "id": 140691549,
                "url": "https://finnhub.io/api/news?id=f082f173ddaac508b1fa41eda4426082acabffc8a9e233f9d83fae63eb15dd75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "News of the day for June 22, 2026",
                "category": "company",
                "datetime": 1782130097,
                "headline": "5 Things to Know Before the Stock Market Opens"
              },
              {
                "id": 140694343,
                "url": "https://finnhub.io/api/news?id=6f16007c3b7bab9c6a6cbd0d62891ed8c7bdbe9a1c160b12f600247ec8dd8f7f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/22/Offshore-oil-and-gas-wellhead-remote-pla.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 points on Monday.\n\n\n\nThe Dow traded up 0.28% to 51,709.06 while the NASDAQ fell 1.31% to 26,170.77. The S&P 500 also",
                "category": "company",
                "datetime": 1782129950,
                "headline": "Crude Oil Falls Over 2%; Getty Images Shares Spike Higher"
              },
              {
                "id": 140691615,
                "url": "https://finnhub.io/api/news?id=b27689a443afba49df3a51b1c4bbefef824c49b26741090cbc9f423edd0431ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel. The first line up of senior level clinical operation executives include: Jennifer Sheller, SVP, Head of Global Clinical Trial Operations, Global Clinical Development",
                "category": "company",
                "datetime": 1782129600,
                "headline": "Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference"
              },
              {
                "id": 140690837,
                "url": "https://finnhub.io/api/news?id=2da5204188e6e6056847d0de8dc71824dc3ff282eb2872c20136c6f329125805",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) (\"Apogee\") today announced they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma. The acquisition complements AbbVie's existing immunology portfolio and accelerates AbbVie's clinical presence in the respiratory space.",
                "category": "company",
                "datetime": 1782126000,
                "headline": "AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio"
              },
              {
                "id": 140693272,
                "url": "https://finnhub.io/api/news?id=aee1bc97f670fc184771c18182e486ea788c86c554c861793ba440d4b3412e5e",
                "image": "https://image.cnbcfm.com/api/v1/image/108324845-2ED1-REQ-062226-NewsOPEN.jpg?v=1782137992&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1782124311,
                "headline": "Market Open: June 22, 2026"
              },
              {
                "id": 140690308,
                "url": "https://finnhub.io/api/news?id=a154e604074c54acde1e216eb7be99f2cb6ddb95b40f80c5955e8496e7573ab7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 12 High Quality Stocks to Buy for the Long Term. On June 16, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over the age of 21. AbbVie said Skinvive […]",
                "category": "company",
                "datetime": 1782120098,
                "headline": "AbbVie’s (ABBV) Allergan Aesthetics Wins FDA Approval for Skinvive by Juvederm"
              },
              {
                "id": 140693084,
                "url": "https://finnhub.io/api/news?id=ddf9fe87ff3b0d9f15276ad23c106d810800944fed27ee9e90642004c80c7515",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/22/MA.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.",
                "category": "company",
                "datetime": 1782119707,
                "headline": "AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition"
              },
              {
                "id": 140690309,
                "url": "https://finnhub.io/api/news?id=38fd4136a0ef585f1caf88f769ca4daa7a356faf547f31d9d573200e5cbb15fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1782118279,
                "headline": "2 Profitable Stocks Worth Your Attention and 1 We Avoid"
              },
              {
                "id": 140691616,
                "url": "https://finnhub.io/api/news?id=956199fe4dbadc46c079f0ebfad09cba0dc57f6e94dc9c73d7de729acaa91222",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.",
                "category": "company",
                "datetime": 1782114540,
                "headline": "AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs"
              },
              {
                "id": 140693435,
                "url": "https://finnhub.io/api/news?id=b3369e1c1e06ce93102aeb0766c24ccaa0e25006e0c8ab03522557371cbab267",
                "image": "https://image.cnbcfm.com/api/v1/image/108321572-1781377484011-IMG_1072.jpeg?v=1781546264&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1782113704,
                "headline": "Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more"
              },
              {
                "id": 140694345,
                "url": "https://finnhub.io/api/news?id=fc4b094147854ccfbd4135d3428b259692c73e3d47a86203570055a7f7bf5124",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead",
                "category": "company",
                "datetime": 1782111767,
                "headline": "AbbVie To Acquire Apogee And Its Diverse Pipeline Of Multiple Clinical-Stage Candidates In Development Across Inflammatory And Immunological Diseases For $135.11/Shr In Cash"
              },
              {
                "id": 140689843,
                "url": "https://finnhub.io/api/news?id=dfe048026825180c50eebedc507affbc325e7a0c399035a2f62b6328675f7119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Don't wait too long to get in on these outstanding dividend payers.",
                "category": "company",
                "datetime": 1782108300,
                "headline": "3 Excellent Dividend Stocks to Buy on the Dip"
              },
              {
                "id": 140694346,
                "url": "https://finnhub.io/api/news?id=2a28a7c777cc71b7c9a56e234eda905d413137e552cf45be0e9763e46c7e5001",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?syn-25a6b1a6=1 ",
                "category": "company",
                "datetime": 1782102283,
                "headline": "Reported Friday, 'AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics' - FT"
              },
              {
                "id": 140689912,
                "url": "https://finnhub.io/api/news?id=c220c8b93ffe9e8047b1b9d6d27017a0034a9bf856cb5f05aff2f568827b8972",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Dividend Kings rebound in June, nearly matching SPY YTD.",
                "category": "company",
                "datetime": 1782101010,
                "headline": "Best Dividend Kings: June 2026"
              },
              {
                "id": 140687069,
                "url": "https://finnhub.io/api/news?id=038182b20706846a8396b0e55102890345a59ae8195727fb4930bad0bb58f9f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026",
                "category": "company",
                "datetime": 1782073047,
                "headline": "The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026"
              },
              {
                "id": 140685295,
                "url": "https://finnhub.io/api/news?id=e48a0147a5ee3a201aafd83b97701fc638ac8f2081e3cabf35860ff2428911ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup ...",
                "category": "company",
                "datetime": 1782054420,
                "headline": "AbbVie's biggest deal since 2019 could land soon"
              },
              {
                "id": 140673043,
                "url": "https://finnhub.io/api/news?id=1486d542178c6437fd6835f7c083b5f7a14c8390fd7844c73aea933861d437f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Ten thousand dollars a month works out to $120,000 a year, an income stream that exceeds the roughly $68,359 in per-capita disposable personal income reported by the Bureau of Economic Analysis for the first quarter of 2026. For many retirees, that level of cash flow would support a lifestyle well above basic needs. The real ... The Retirement Portfolio That Forks Over a $10,000 Check Every Month",
                "category": "company",
                "datetime": 1781895387,
                "headline": "The Retirement Portfolio That Forks Over a $10,000 Check Every Month"
              },
              {
                "id": 140668878,
                "url": "https://finnhub.io/api/news?id=cb56ea8f77ad894ace0f2218ea7e2c3368f8632132870ac6f8070f28febe0975",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Bloomberg) -- Global stocks are ending a strong week on a cautious note as relief over an interim peace deal between the US and Iran gave way to a focus on the hurdles that remain to secure a lasting agreement.Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingTrump Blows Through His Iran Red Lines in Justifying Peace DealUS and Iran Delay Nuclear Talks as Lebanon Clashes WorsenUS Tells ASML It’s Concerned Ch",
                "category": "company",
                "datetime": 1781883280,
                "headline": "Stocks Slide as Focus Shifts to Iran Deal Hurdles: Markets Wrap"
              },
              {
                "id": 140670033,
                "url": "https://finnhub.io/api/news?id=f27878b3367e2d91e08065f74b2d12defe2aa81e808c355481779009263bd2df",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2210847096/image_2210847096.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie stock stays a buy on FDA approvals, strong R&D, and rising Venclexta revenue. Click here to read more on the ABBV stock.",
                "category": "company",
                "datetime": 1781862683,
                "headline": "AbbVie: Immunology Cash Flow Funds Oncology Expansion"
              },
              {
                "id": 140667013,
                "url": "https://finnhub.io/api/news?id=40038816fa54cd490942c62bfb04c763452a018b9dcd1c1764d125cf2b04ce44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.",
                "category": "company",
                "datetime": 1781830588,
                "headline": "How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story"
              },
              {
                "id": 140666619,
                "url": "https://finnhub.io/api/news?id=6ae8bcbd6b142658ab07f31142a28adccc3d1c6fa67cbde90455bc2da5f1f8dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The US Food and Drug Administration said Thursday it is requesting updates to prescribing informatio",
                "category": "company",
                "datetime": 1781819791,
                "headline": "FDA Seeks Updated Labeling for Testosterone Therapies"
              },
              {
                "id": 140666620,
                "url": "https://finnhub.io/api/news?id=fba3d4ec92a1b32d417c4ace40e24eac85da760e5b379277132fb94337e20d69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In the most recent trading session, AbbVie (ABBV) closed at $216.49, indicating a -2.14% shift from the previous trading day.",
                "category": "company",
                "datetime": 1781819102,
                "headline": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 140665981,
                "url": "https://finnhub.io/api/news?id=0b638c6ef191f5dbe4acd9d2334545c22003192c9ec27ab3ef212175c49ee56a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.",
                "category": "company",
                "datetime": 1781816249,
                "headline": "What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine?"
              },
              {
                "id": 140665998,
                "url": "https://finnhub.io/api/news?id=63985f73ebf3fbd6c5f3758fc987c8932425b699c75ae4cacc4404a4c36729d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.",
                "category": "company",
                "datetime": 1781813100,
                "headline": "AbbVie Declares Quarterly Dividend"
              },
              {
                "id": 140671475,
                "url": "https://finnhub.io/api/news?id=04c7499d656cafdfb442d13e8677cc5baa001c9ba76b98009765eeed5ac4b408",
                "image": "https://image.cnbcfm.com/api/v1/image/108324290-17818192661781819251-46629128711-1080pnbcnews.jpg?v=1781819265&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "Michael Yee, UBS global head of biotech research, joins 'Fast Money' to talk the biotech sector.",
                "category": "company",
                "datetime": 1781805250,
                "headline": "Surge in biotech being driven by M&A, says UBS's Michael Yee"
              },
              {
                "id": 140661963,
                "url": "https://finnhub.io/api/news?id=c310ad8bce4ee2274e1f7174fc5fe1843735f12bb0df695be7b43742420deaba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "WATERTOWN, Mass., June 18, 2026--Today, Portal Biotechnologies, Inc. (\"Portal\"), a cell engineering and drug discovery platform company, announced updates on significant commercial progress and the closing of an oversubscribed $9M financing round led by NFX and participation from existing investors including IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures.",
                "category": "company",
                "datetime": 1781782200,
                "headline": "Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers"
              },
              {
                "id": 140662039,
                "url": "https://finnhub.io/api/news?id=461b6192c5d91598515da2627afc42cb4b4b2187328e7904e81551d04034bcaa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) reported positive Phase 3 results for a venetoclax-based combination in untreated chronic lymphocytic leukemia in less-fit patients. The company also received U.S. FDA approval for SKINVIVE by JUVÉDERM for reducing neck lines and improving neck appearance. AbbVie operates at the intersection of large-scale pharmaceuticals and medical aesthetics, with products that span immunology, oncology, neuroscience and cosmetic treatments. The latest data in chronic lymphocytic...",
                "category": "company",
                "datetime": 1781781233,
                "headline": "AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress"
              },
              {
                "id": 140661855,
                "url": "https://finnhub.io/api/news?id=5e7923cb7cbb8ebf12e23d75ac6ca50da2671a001d9cc1305a302d493fbf026a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2265088343/image_2265088343.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "ABIVAX plans NDA submission for obefazimod in Q4 2026, with Crohn’s disease Phase 2b data delayed to mid-2027. Learn why ABVX stock is a strong sell.",
                "category": "company",
                "datetime": 1781765611,
                "headline": "Abivax: Safety Signals Loom Ahead Of The NDA Submission"
              },
              {
                "id": 140656174,
                "url": "https://finnhub.io/api/news?id=2aa3c28a6316d21cd0b3a250dbcd7a34faab4f462d8a0077eef69088034ae1a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.",
                "category": "company",
                "datetime": 1781720514,
                "headline": "Eli Lilly Stock's Trillion-Dollar Question"
              },
              {
                "id": 140654878,
                "url": "https://finnhub.io/api/news?id=8f05bed92f1922253f4af2a9cccf5a2368e3e92971ad7785cdd048500f5fd5d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association 2026 Congress in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic […]",
                "category": "company",
                "datetime": 1781717687,
                "headline": "AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination"
              },
              {
                "id": 140654833,
                "url": "https://finnhub.io/api/news?id=0af54b09cc456b697d54b1cbe3268af507e3f7ce906b018927f8e52bf8c00d41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.",
                "category": "company",
                "datetime": 1781716091,
                "headline": "The Number That Could Test Johnson & Johnson Stock"
              },
              {
                "id": 140654836,
                "url": "https://finnhub.io/api/news?id=75650634439443a1b3278415e11c94f5fd9a43ed9188da817a87e5cdb95ed5fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.",
                "category": "company",
                "datetime": 1781711865,
                "headline": "Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished"
              },
              {
                "id": 140653537,
                "url": "https://finnhub.io/api/news?id=2caee55af96ff8785a0c4c923010e58bcbd5b081a61aa6d040a27bbd86621ec5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1781701207,
                "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140651935,
                "url": "https://finnhub.io/api/news?id=46a48ecaf76bf483ab2ae918516ac62a9a2f02deb403f32356f92edfec73ecc8",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "A technical breakout strategy combining strong uptrend stocks with tight consolidation patterns for low-risk entry points, using AbbVie (ABBV) as a key example.",
                "category": "company",
                "datetime": 1781697633,
                "headline": "AbbVie Inc (NYSE:ABBV) Breakout Setup Combines Strong Technical Rating with High-Quality Consolidation Entry"
              },
              {
                "id": 140648789,
                "url": "https://finnhub.io/api/news?id=4528b8277e0ac4ba708657e6d8b62a3bfdb5bc27784f20f113e53af2fa7bf8eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV) just got a lot easier to answer. The company posted $15.002 billion in Q1 2026 revenue, beating consensus by $284 million, and management raised full-year adjusted EPS guidance to $14.08 to $14.28. With the stock yielding nearly 3%, the question is whether the ... This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie",
                "category": "company",
                "datetime": 1781642530,
                "headline": "This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie"
              },
              {
                "id": 140648633,
                "url": "https://finnhub.io/api/news?id=e9215a70b8ae0be912b3b645fc4e1e6f63425eb850164ef686d0cb2f794e7fd6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2281492509/image_2281492509.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) outlook: Skyrizi & Rinvoq drive growth as Humira fades. Read the full analysis here.",
                "category": "company",
                "datetime": 1781631117,
                "headline": "AbbVie: Maintaining My Strong Buy Rating After Label Expansion"
              },
              {
                "id": 140646735,
                "url": "https://finnhub.io/api/news?id=56f603e84e098099b22e20190fbb273e3c82e1f303323ba1befd92c888556887",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has quietly become one of healthcare’s most underrated growth stories. CEO Robert A. Michael told investors after Q1, “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations.” The numbers back him up. Immunology revenue hit $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%. Yet shares ... AbbVie Stock Will Hit $300 on This Date",
                "category": "company",
                "datetime": 1781631018,
                "headline": "AbbVie Stock Will Hit $300 on This Date"
              },
              {
                "id": 140646856,
                "url": "https://finnhub.io/api/news?id=f005ee48bfae08da1af5f122eba145b687e00876f41af7c1e8f04c5e295f63d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "MONTPELLIER, France, June 16, 2026--Medincell (Paris:MEDCL): Key Financial Highlights",
                "category": "company",
                "datetime": 1781624700,
                "headline": "Medincell Reports FY 2025-26 Annual Results"
              },
              {
                "id": 140645583,
                "url": "https://finnhub.io/api/news?id=590df706c93efd585fa5bd7443d7726faf1ebccb4cf06c4fc79e07e31968c7f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
                "category": "company",
                "datetime": 1781616603,
                "headline": "Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet"
              },
              {
                "id": 140644888,
                "url": "https://finnhub.io/api/news?id=6eaabbb32fce2118aaf335297d381764ea1473629163110554ba198cd10e0b26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.",
                "category": "company",
                "datetime": 1781615221,
                "headline": "Health Care ETFs: XLV Delivers Low Fees and Solid Returns"
              },
              {
                "id": 140644928,
                "url": "https://finnhub.io/api/news?id=9c3af55c8fd198ca9e3b97fd56771c27dbe974371e0fb3d51ec19943a3347e02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture, leading to an improved neck appearance.1",
                "category": "company",
                "datetime": 1781611200,
                "headline": "Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance"
              },
              {
                "id": 140644492,
                "url": "https://finnhub.io/api/news?id=aea063c683d3be2206d11db2fc7b4e66532830a35d3be00e5b9ebd4a2b6713ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for 41% of the fund’s $71.6 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns ... SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It",
                "category": "company",
                "datetime": 1781604773,
                "headline": "SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It"
              },
              {
                "id": 140647743,
                "url": "https://finnhub.io/api/news?id=ee68a3f28b1072c45cc0a9716f8d74762d8538cc84bc9f541057b6aa941d913d",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults",
                "category": "company",
                "datetime": 1781596941,
                "headline": "AbbVie's Allergan Aesthetics Receives FDA Approval For SKINVIVE By JUVÉDERM To Reduce Neck Lines To Enhance Neck Appearance In Adults Over Age 21"
              },
              {
                "id": 140639627,
                "url": "https://finnhub.io/api/news?id=812c951494e243a7131ed960df204ec414f40e3caa1cbca1394f9471b06b3ded",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Two retirees walk into retirement with the same amount of money. One builds a portfolio that pays $120,000 a year but barely grows. The other settles for $65,000 a year and focuses on dividend growth. At first glance, the first retiree appears to have won. Twenty-five years later, the second retiree may have collected more ... The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer",
                "category": "company",
                "datetime": 1781549965,
                "headline": "The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer"
              },
              {
                "id": 140638896,
                "url": "https://finnhub.io/api/news?id=54cebd268783a5d88980e6b1060c5d8694770c1473fe189ec6de93e2541f8544",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.",
                "category": "company",
                "datetime": 1781545147,
                "headline": "3 Stocks Estimated To Be Up To 46.2% Below Fair Value Offering A 12.2% Discount Opportunity"
              },
              {
                "id": 140638798,
                "url": "https://finnhub.io/api/news?id=3b5a5ccec14fdf2cc6423edabdac28bbcff8beb167504701c5780dbf58d3e0b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) was built for investors who want a paycheck that gets bigger every year, not a yield chase. DGRO tracks the Morningstar US Dividend Growth Index, screening for companies with at least five consecutive years of dividend growth and payout ratios under 75%. The fund pays a roughly 2.2% ... 64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends",
                "category": "company",
                "datetime": 1781542560,
                "headline": "64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends"
              },
              {
                "id": 140637911,
                "url": "https://finnhub.io/api/news?id=34c50db6c012e281a570b6af876f88fe84a025c86611854903a3f549ad77be5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.",
                "category": "company",
                "datetime": 1781532240,
                "headline": "Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?"
              },
              {
                "id": 140636737,
                "url": "https://finnhub.io/api/news?id=62287e5fcdfa070b0f1a08c2fd9d9236f9f1d3ced83a1999d83ae3f16f73d20c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Over the last 7 days, the United States market has remained flat, yet it is up 24% over the past year with earnings anticipated to grow by 19% annually in the coming years. In this context of robust growth expectations, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.",
                "category": "company",
                "datetime": 1781523522,
                "headline": "June 2026's Noteworthy Stocks Estimated Below Intrinsic Value"
              },
              {
                "id": 140636467,
                "url": "https://finnhub.io/api/news?id=2d5aa1e8efd0394197166a84fc453b65eea5c66fe6aff254de1b4c1df526f36c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Now's the time to load up on these high-yielders.",
                "category": "company",
                "datetime": 1781514240,
                "headline": "3 High-Yield Dividend Stocks to Buy Hand Over Fist in June"
              },
              {
                "id": 140627804,
                "url": "https://finnhub.io/api/news?id=2333023d5a79f2c2d24c5654b4cab4972476bfcb9c8a55acf5b91bf02531f080",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If you are wondering whether AbbVie at around US$227.73 is still offering fair value, the starting point is to understand what the current price actually reflects. The stock has inched up 0.2% over the past week and 9.2% over the last month, while the year to date return is slightly down 0.7% and the 1 year, 3 year and 5 year returns sit at 23.1%, 82.9% and 142.8% respectively. These moves have kept AbbVie on the radar as investors weigh long term performance against current pricing. Recent...",
                "category": "company",
                "datetime": 1781359786,
                "headline": "AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73"
              },
              {
                "id": 140627209,
                "url": "https://finnhub.io/api/news?id=e009683d22a2f708130a5a7f1e8f34b36945fe0ae449a6835641fcb15e2f529d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date even after a 6% one-month bounce. That stagnation has left a handful of high-margin operators trading at forward multiples that look out of ... 3 Ridiculously Cheap Healthcare Stocks to Buy in June",
                "category": "company",
                "datetime": 1781357428,
                "headline": "3 Ridiculously Cheap Healthcare Stocks to Buy in June"
              },
              {
                "id": 140627241,
                "url": "https://finnhub.io/api/news?id=0b51978df099617cefd9651fea7344a6ea091638629442c982afb1b364d96360",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Paying $2,000 a month in rent is often described as throwing money away. Homeownership, by contrast, is treated as the only reliable path to wealth. Yet under the right conditions, a dividend portfolio large enough to cover your rent can leave you with greater flexibility and, in some cases, a larger net worth than owning ... Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years",
                "category": "company",
                "datetime": 1781352132,
                "headline": "Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years"
              },
              {
                "id": 140624159,
                "url": "https://finnhub.io/api/news?id=b21fabc56e70295326569dcad9d0b0b445fe5c409a4bc43532b49f160b3b6d16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.",
                "category": "company",
                "datetime": 1781300702,
                "headline": "AbbVie (ABBV) Rises Higher Than Market: Key Facts"
              },
              {
                "id": 140623024,
                "url": "https://finnhub.io/api/news?id=4c1cecfc6a5b34f3242c9306a4411f15028914ca85f4742fa17b7bb6e2552a12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.",
                "category": "company",
                "datetime": 1781297590,
                "headline": "What Could Push JNJ Stock Higher From Here?"
              },
              {
                "id": 140621658,
                "url": "https://finnhub.io/api/news?id=2e2a3fc7e7a4d422193e4c2989be6faac1d902220b3f9aa978156c6b7de72b37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.",
                "category": "company",
                "datetime": 1781291663,
                "headline": "JNJ Raised the Bar: So Why Is the Stock Standing Still?"
              },
              {
                "id": 140620236,
                "url": "https://finnhub.io/api/news?id=79271cf1f3840d270d35f54fad5b650934e9e29c44f5017178c27aa5f5137cb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Over the last 7 days, the United States market has dropped 2.4%, yet it remains up by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying undervalued stocks can be particularly appealing as they may offer significant potential for appreciation when their intrinsic value is recognized by the market.",
                "category": "company",
                "datetime": 1781285880,
                "headline": "3 Stocks Estimated To Be Up To 47.8% Below Intrinsic Value"
              },
              {
                "id": 140621660,
                "url": "https://finnhub.io/api/news?id=f8b5833ae5cd5c0710eeadfbc082ec40dd987f82e4d361ab7dca811157ff0548",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.",
                "category": "company",
                "datetime": 1781285513,
                "headline": "The Catch Hiding In Eli Lilly Stock's Growth Story"
              },
              {
                "id": 140616607,
                "url": "https://finnhub.io/api/news?id=285620556dfbbb7b6bfaa263852c867445917216c5ab514a6536f621ab625305",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Over the last 7 days, the United States market has dropped 2.4%, though it has risen by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying stocks that might be trading below their estimated intrinsic value can present potential opportunities for investors looking to capitalize on undervalued assets.",
                "category": "company",
                "datetime": 1781264282,
                "headline": "3 Stocks That Might Be Up To 39.8% Below Their Estimated Intrinsic Value"
              },
              {
                "id": 140616536,
                "url": "https://finnhub.io/api/news?id=5ec0dba7b2e538562a198030ab89184d33dc6c2a0ead6cc06a01802d44b4a988",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If you own JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), you bought it for a reason that still holds. JEPI pays monthly. It leans on a defensive equity sleeve and runs a covered call overlay that turns volatility into income. It is the largest active ETF in the country, yielding near 8.2%. But a younger competitor now runs the same ... Forget JEPI, Goldman’s S&P Income ETF Has Beaten It by 42 Points Since Launch",
                "category": "company",
                "datetime": 1781263405,
                "headline": "Forget JEPI, Goldman’s S&P Income ETF Has Beaten It by 42 Points Since Launch"
              },
              {
                "id": 140616546,
                "url": "https://finnhub.io/api/news?id=9aec43a641625d72ca7e24bc0fa335aef6022ac8a68cc22492ee500914c8eff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "New cancer therapies may help fund dividend growth.",
                "category": "company",
                "datetime": 1781260500,
                "headline": "AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend."
              },
              {
                "id": 140618341,
                "url": "https://finnhub.io/api/news?id=cf14145472ccb201f661c1e008901405e6b1bb5c8729b543e5fc61bbc5828eb6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/12/Abbvie.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie says nine-year CLL14 data showed longer progression-free survival with venetoclax plus obinutuzumab in chronic lymphocytic leukemia.",
                "category": "company",
                "datetime": 1781260254,
                "headline": "AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients"
              },
              {
                "id": 140617959,
                "url": "https://finnhub.io/api/news?id=72df163989eb2ecbee48dd3cf874fc0b4e646f13b0a4457f5e7c70f37d267be9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412857430/image_1412857430.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie replaced Humira with Skyrizi/Rinvoq, but debt and pipeline risks keep it a hold. Click here to read this latest analysis of ABBV stock.",
                "category": "company",
                "datetime": 1781260096,
                "headline": "AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy"
              },
              {
                "id": 140618161,
                "url": "https://finnhub.io/api/news?id=d755d25502b61f670e79eaf09cfbae8762d32271a8cda34e783f6a273b1aaea9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/12/Healthcare-stocks.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst takes on top stocks, sorted by accuracy.",
                "category": "company",
                "datetime": 1781249444,
                "headline": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields"
              },
              {
                "id": 140615528,
                "url": "https://finnhub.io/api/news?id=68e641bfba64dd0e9923291cd8b47424bbd195f88c4643b5bd186f41aa0ae8ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation.",
                "category": "company",
                "datetime": 1781247600,
                "headline": "AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 250,
            "discarded_article_count": 218
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.6,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(20.7%→15.6%)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 7873036.666666667,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 12694440,
              "avg_vol_20": 9082345,
              "avg_vol_30": 7873036.666666667,
              "range_pct_10": 0.1559003006440331,
              "range_pct_20": 0.18170041946595017,
              "range_pct_30": 0.20675437686056852,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.6123943704906747,
              "dist_to_20d_high": 0.02671617387570049,
              "down_shrink_days": 2,
              "breakout_level_20d": 261.64001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7540362773029443
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.896132059537878,
              "turnoverUsdM": 932.5603492787401,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.ABBV",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 239.9,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.8,
            "take_profit_price": 270.0637,
            "target_multiplier": 1.9,
            "technical_strength": 1.65,
            "take_profit_percent": 6.1
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.792264119075756,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 7.375,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.9
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 105.65
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "強累積",
      "score": 10,
      "value": 0.3712
    },
    "kdj": {
      "d": 86.07,
      "j": 78.18,
      "k": 83.44,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 69.39
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 76463774,
      "recentSlope": 6086807.4,
      "previousSlope": 231940
    },
    "rsi": 75.68,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 240.9546,
      "position": "SAR喺價下",
      "distancePct": 5.38,
      "previousTrend": "上升"
    },
    "ma50": 220.7796,
    "macd": {
      "macd": 10.547382208783262,
      "trend": "強烈看漲",
      "signal": 8.708674627083784,
      "histogram": 1.8387075816994773
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 240.7093,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 11
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.41,
      "score": 2,
      "avgVolume": 8953006,
      "currentVolume": 3662126
    },
    "derived": {
      "ma20": 236.568,
      "ma50": 220.7796,
      "prevClose": 254.76,
      "avgVolume10": 12069373,
      "avgVolume20": 8953006,
      "changePercent": -0.04,
      "avgVolumeForScore": 8953006
    },
    "ma_cross": {
      "ma20": 236.568,
      "ma50": 220.7796,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 235.197,
      "prevMa50": 219.7056,
      "spreadPct": 7.15,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 207.9171,
      "upper": 265.2189,
      "position": "上半部"
    },
    "rsi_short": 53.15,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.41
    }
  }
}

{
  "close": 254.65,
  "volume": 3662126,
  "changePercent": -0.04
}